

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

## **The prolactin receptor scaffolds Janus kinase 2 via co-structure formation with phosphoinositide-4,5-bisphosphate**

Raul Araya-Secchi<sup>1,2</sup>, Katrine Bugge<sup>3#</sup>, Pernille Seiffert<sup>3#</sup>, Amalie Petry<sup>4</sup>, Gitte W. Haxholm<sup>3</sup>,  
Kresten Lindorff-Larsen<sup>3</sup>, Stine F. Pedersen<sup>4\*</sup>, Lise Arleth<sup>1\*</sup> and Birthe B. Kragelund<sup>3\*</sup>,

<sup>1</sup>Structural Biophysics, Section for Neutron and X-ray Science, Niels Bohr Institute, University of  
Copenhagen, 2100 Copenhagen, Denmark.

<sup>2</sup>Facultad de Ingenieria Arquitectura y Diseño, Universidad San Sebastian, Bellavista 7, Santiago,  
Chile.

<sup>3</sup>Structural Biology and NMR Laboratory (SBiNLab), Department of Biology, University of  
Copenhagen, 2200 Copenhagen, Denmark.

<sup>4</sup>Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, 2200  
Copenhagen N, Denmark

#contributed equally

\*Corresponding author: [bbk@bio.ku.dk](mailto:bbk@bio.ku.dk).

Correspondence also to [arleth@nbi.ku.dk](mailto:arleth@nbi.ku.dk) and [sfpedersen@bio.ku.dk](mailto:sfpedersen@bio.ku.dk)

Running title: Co-structure formation by PRLR, JAK2 and PI(4,5)P<sub>2</sub>

34 **Abstract**

35 Class 1 cytokine receptors transmit signals through the membrane by a single transmembrane helix  
36 to an intrinsically disordered cytoplasmic domain that lacks kinase activity. While specific binding  
37 to phosphoinositides has been reported for the prolactin receptor (PRLR), the role of lipids in PRLR  
38 signalling is unclear. Using an integrative approach combining NMR spectroscopy, cellular signalling  
39 experiments, computational modelling and simulation, we demonstrate co-structure formation of the  
40 disordered intracellular domain of the human PRLR, the membrane constituent phosphoinositide-4,5-  
41 bisphosphate (PI(4,5)P<sub>2</sub>) and the FERM-SH2 domain of the Janus kinase 2 (JAK2). We find that the  
42 complex leads to accumulation of PI(4,5)P<sub>2</sub> at the transmembrane helix interface and that mutation  
43 of residues identified to interact specifically with PI(4,5)P<sub>2</sub> negatively affects PRLR-mediated  
44 activation of signal transducer and activator of transcription 5 (STAT5). Facilitated by co-structure  
45 formation, the membrane-proximal disordered region arranges into an extended structure. We suggest  
46 that the co-structure formed between PRLR, JAK2 and PI(4,5)P<sub>2</sub> locks the juxtamembrane disordered  
47 domain of the PRLR in an extended structure, enabling signal relay from the extracellular to the  
48 intracellular domain upon ligand binding. We find that the co-structure exists in different states which  
49 we speculate could be relevant for turning signalling on and off. Similar co-structures may be relevant  
50 for other non-receptor tyrosine kinases and their receptors.

51


52 **Keywords:** IDP, NMR, simulation, prolactin receptor, JAK2, single-pass transmembrane receptors,  
53 PI(4,5)P<sub>2</sub>,

54

55

56 **Introduction**

57 Cytokine receptors are transmembrane glycoproteins that bind cytokines on the cell surface and  
58 transduce signals across the membrane to the interior of the cell. This, in turn, activates signalling  
59 pathways leading to multiple outcomes including induction of immune responses, cell proliferation,  
60 altered metabolism and differentiation (Brooks et al., 2016). Class 1 cytokine receptors constitute a  
61 subclass of receptors that transverse the membrane by a single  $\alpha$ -helical transmembrane domain  
62 (TMD) (Brooks et al., 2016), separating a folded extracellular domain (ECD) from a disordered  
63 intracellular domain (ICD). The prolactin (PRL) receptor (PRLR) is one of the structurally most  
64 simple cytokine receptors (**Figure 1**). Signaling by the PRLR/PRL complex is implicated in the  
65 regulation of more than 300 biological functions in vertebrates (Bole-Feysot et al., 1998), and its  
66 function is especially well-known for its essential role in mammary gland development and lactation  
67 (Hannan et al., 2022). Apart from this, deregulation of PRLR/PRL signalling is associated with  
68 several pathologies in humans of which hyperprolactinemia resulting in reproductive failure is best  
69 described (Bachelot and Binart, 2007; Newey et al., 2013). Deregulation of PRLR/PRL signaling is  
70 linked to other diseases and, although still debated, suggested to be implicated in the development  
71 and progression of prostate (Sackmann-Sala and Goffin, 2015) and breast (Clevenger and Rui, 2022)  
72 cancers.



73  
74  
75 **Fig. 1: Schematics of the PRLR:PRL:JAK2 complex in the membrane.** The PRLR is shown in light blue, the PRL as  
76 a dark blue triangle, the PRLR-ICD as a disordered chain and JAK2 in purple. The PI(4,5)P<sub>2</sub> lipid (PIP<sub>2</sub>) is shown in  
77 orange. The intracellular juxtamembrane (ICJM) region and BOX1 of PRLR-ICD are highlighted in green nuances, while  
78 the three LIDs as defined in Haxholm et al., (Haxholm et al., 2015) are highlighted in red. For simplicity only one of the  
79 two ICDs is shown associated with JAK2 via the BOX1 (green) and BOX2 (orange) motifs.  
80

81 For cytokine receptors, signal transduction through the membrane is received by an ICD, which is  
82 intrinsically disordered and lacks kinase activity (Haxholm et al., 2015). Thus, association of

83 auxiliary kinases is mandatory for signalling, with the Janus kinases (JAK1–3) and the tyrosine kinase  
84 TYK2 being the most thoroughly described (Brooks et al., 2016; Morris et al., 2018). A proline-rich  
85 region constituting the so-called BOX1 motif close to the membrane, as well as a second hydrophobic  
86 motif termed BOX2, are known to be essential for JAK binding (**Figure 1**) (Ferrao et al., 2018;  
87 Rowlinson et al., 2008). However, although progress has been made in the molecular understanding  
88 of cytokine binding and despite several structures of folded ECDs (Broutin et al., 2010; de Vos et al.,  
89 1992), TMDs (Bocharov et al., 2018; Bugge et al., 2016), a complete receptor (Kassem et al., 2021)  
90 and a receptor ICD in complex with JAK1 (Glassman et al., 2022) have emerged, it is still not clear  
91 how the signal inside the cell is received by the disordered region to elicit and in turn control signal  
92 transduction.

93  
94 A subset of class 1 cytokine receptors form homodimers and trimeric complexes with their ligands,  
95 with the main dimerization occurring in the TMDs (Brooks et al., 2014; Brown et al., 2005; Gadd  
96 and Clevenger, 2006; Kubatzky et al., 2001; Seubert et al., 2003). This group includes the growth  
97 hormone receptor (GHR), the erythropoietin receptor (EPOR), the thrombopoietin receptor (TPOR)  
98 and the PRLR, which have become well-established paradigmatic models. Recently, signal  
99 transduction by the GHR has been suggested to occur via a rotation of the transmembrane helices  
100 within the dimer leading to a subsequent separation of the ICDs (Brooks et al., 2014; Brown et al.,  
101 2005). A torque is hereby exerted on the associated JAK2s, which is thought to relieve inhibition by  
102 the pseudokinase domains, initiating signalling. The ICDs of these receptors have been shown to be  
103 highly disordered (Haxholm et al., 2015), a feature which is preserved in models of the PRLR (Bugge  
104 et al., 2016) and the full-length GHR in nanodiscs (Kassem et al., 2021). This brings forward the  
105 question of how signalling is orchestrated by disorder and how a disordered linker region between  
106 the TMD and the region bound to the kinases can communicate and transduce information.

107  
108 For both the PRLR and the GHR, lipid interaction domains (LID) with affinity for negatively charged  
109 lipids have been identified in their ICDs (Haxholm et al., 2015). Common to both receptors is that  
110 they contain a LID proximal to the membrane, directly overlapping with the JAK2 interaction sites,  
111 BOX1 and BOX2 (Seiffert et al., 2020). Using nuclear magnetic resonance (NMR) spectroscopy we  
112 identified three LIDs in the PRLR-ICD termed LID1, LID2 and LID3 (**Figure 1**) (Haxholm et al.,  
113 2015) and using lipid dot-blots we showed that the PRLR-ICD has variable affinities for different  
114 membrane constituents, including for different phosphoinositides (PIs). In particular, PRLR has a  
115 distinct affinity for phosphoinositide-4,5-bisphosphate (PI(4,5)P<sub>2</sub>) and lacks affinity for PI(3,4,5)P<sub>2</sub>  
116 (Haxholm et al., 2015). PIs are important constituents of the membrane and play key roles in  
117 signalling, both as membrane interaction partners that can be specifically modulated by  
118 phosphorylation (Carracedo and Pandolfi, 2008), and as secondary messengers (McLaughlin et al.,  
119 2002; Suh and Hille, 2005). Indeed, some single-pass receptors contain conserved anionic lipid  
120 interaction sites close to the membrane (Hedger et al., 2015a) and increasing evidence suggest lipid  
121 interaction to take on important regulatory roles (McLaughlin et al., 2005; Metcalf et al., 2010).  
122 Recently, the epidermal growth factor receptor (EGFR) was shown to sequester PI(4,5)P<sub>2</sub> by  
123 accumulating it around the TMD regulating the dimer/monomer equilibrium and with a possible  
124 positive feedback loop through the activation of the phospholipase C (PLC) – diacylglycerol (DAG)-

125 IP<sub>3</sub> pathways (Maeda et al., 2018). This will lead to subsequent conversion of PI(4,5)P<sub>2</sub> to PI(3,4,5)P<sub>3</sub>  
126 and hence depletion of PI(4,5)P<sub>2</sub> from the membrane. Similar depletion of PI(4,5)P<sub>2</sub> from the plasma  
127 membrane has been noted under hypoxia (Lu et al., 2022). For class 1 cytokine receptors the role of  
128 PIs in signalling is less clear.

129  
130 In a cellular context, signalling-related proteins can be membrane anchored through modifications  
131 such as acylation (Patwardhan and Resh, 2010; Rawat et al., 2013; Rawat and Nagaraj, 2010) or via  
132 designated lipid-binding domains. This includes the four point-1, ezrin, radixin moesin (FERM)  
133 domain of radixin, focal adhesion kinase (FAK) and the protein tyrosine phosphatase L1 (PTPL1)  
134 (Bompard et al., 2003; Feng and Mertz, 2015; Hamada et al., 2000), the SH2 domains of the Src  
135 family kinases (Park et al., 2016; Sheng et al., 2016) and the FERM-SH2 domain of merlin (Mani et  
136 al., 2011). Thus, kinases and receptors can co-localize at the plasma membrane without necessarily  
137 being bound within a complex. It is, however, unclear whether such membrane co-localisation has  
138 functional consequences, such as enhancing signalling speed, and whether the membrane may act as  
139 an additional scaffolding platform that enhances binding via restriction in the two-dimensional plane.

140  
141 Recent work on disorder in membrane proteins and on the interplay between membrane proteins and  
142 lipids have revealed the need for strong integrative methods, combining successfully various  
143 structural biology techniques, biophysics and computational biology (Basak et al., 2022; Larsen et  
144 al., 2022). These include NMR, small-angle X-ray scattering, crosslinking-mass spectrometry and  
145 single molecule fluorescence combined with molecular dynamics simulations (Chavent et al., 2018;  
146 Goretzki et al., 2023). These efforts have provided important insights into the role of lipids in  
147 regulation of membrane proteins. For TRPV4, a member of the TRP vanilloid channel family, it was  
148 shown that an autoinhibitory patch of the receptor competed with PI(4,5)P<sub>2</sub> binding at the membrane  
149 to attenuate channel activity, and MD simulation showed that lipid binding affected the ensemble  
150 dynamics (Goretzki et al., 2023). For EphA2, a receptor tyrosine kinase, an integrative study showed  
151 how PIs mediate the interaction between the kinase domains, facilitated by clustering of PIPs via  
152 binding to the receptor juxtamembrane domain (Chavent et al., 2018) further promoting conformation  
153 specific dimerization (Stefanski et al., 2021). Thus, studying dynamic processes at the membrane  
154 interface is an emerging field requiring integrative structural biology approaches for detailed atomic  
155 resolution information.

156  
157 For the PRLR it is still not clear whether, and if so how, interactions between the ICD and the  
158 membrane impact signal transduction and association with JAK2. Nor is it understood how structural  
159 disorder can relay and transmit information from the TMD to initiate signalling. To shed light on the  
160 molecular details underlying a potential interplay between the receptor, membrane and kinase we  
161 focused on the human PRLR and its LID1 closest to the membrane, facilitating the first intracellular  
162 step in signaling. Using an integrative approach combining NMR spectroscopy, cell biology and  
163 computational modelling, we demonstrate the formation of a co-structure comprised of the disordered  
164 PRLR-ICD, the membrane constituent PI(4,5)P<sub>2</sub> and the FERM-SH2 domain of the JAK2. Facilitated  
165 by this co-structure, the disordered region closest to the membrane forms an extended structure, which

166 we suggest stabilizes the disordered domain, allowing signal relay from the extracellular to the  
167 intracellular domain.


168

## 169 **Results**

### 170 **LID1 is disordered in solution and when tethered to the transmembrane helix**

171 Membrane interactions by PRLR-ICD have previously been studied in the absence of anchoring to  
172 the TMD defining three LIDs, with LID1 closest to the membrane (Haxholm et al., 2015). Since  
173 tethering would increase the local concentrations at the membrane and the ICD, this could affect  
174 affinity, complex lifetime as well as the degree by which structure formation would be captured.  
175 Furthermore, the first LID, LID1, is disordered and is located in the juxtamembrane region where it  
176 is responsible for transmitting information on extracellular hormone binding to the bound JAK2. As  
177 this constitutes the very first step on the intracellular side, and given the distance to the other two  
178 LIDs (LID2 and LID3) and their disconnect from the TMD by long disordered regions, we focused  
179 exclusively on LID1. We recombinantly expressed the TMD (residues 211–235 with numbering  
180 corresponding to the processed protein) with five residues added at the two termini (TMD<sub>F206-V240</sub>),  
181 and the TMD with the first 35 residues of LID1, TMD-ICD<sub>F206-S270</sub> (**Figure 2A**). We then examined  
182 their structural propensities in detergents and in small unilamellar vesicles (SUVs) by NMR  
183 spectroscopy. In 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) micelles, most of the TMD  
184 resonances of the TMD<sub>F206-V240</sub> and TMD-ICD<sub>F206-S270</sub> variants were readily superimposable in the  
185 <sup>15</sup>N,<sup>1</sup>H-HSQC spectra (**Figure 2 - figure supplement 1**), suggesting that the conformation of the TMD  
186 was not affected by the presence of the ICD. For the TMD-ICD<sub>F206-S270</sub>, C<sup>α</sup> NMR resonances were  
187 collected for most of the disordered region, while backbone carbon resonances for the TMD, except  
188 for A222, and the region G236-P246 immediately following it, were broadened beyond detection in  
189 the 3D spectra, preventing assignments (**Figure 2B**). This may suggest that the first ten residues of  
190 the ICD interact with or are buried in the micelles, or are affected by the overall slower tumbling of  
191 the micelle, whereas the complete overlap of the TMD residues in the <sup>15</sup>N-HSQC spectra confirm the  
192 helical structure as seen previously. We assigned the backbone nuclei of the detectable resonances of  
193 TMD-ICD<sub>F206-S270</sub> in DHPC micelles and compared the secondary chemical shifts (SCS) to those of  
194 the ICD alone (ICD<sub>G236-Q396</sub>) (**Figure 2C**). Whereas the region of the ICD that is undetected in TMD-  
195 ICD<sub>F206-S270</sub> formed transient extended structures in the absence of the TMD, the observable parts  
196 were highly similar suggesting lack of structure induction by TMD tethering or the micelles. In 1-  
197 palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) SUVs, only the resonances of the most C-  
198 terminal residues of TMD-ICD<sub>F206-S270</sub> were detectable; however, the chemical shifts suggested that  
199 the residues were disordered (**Figure 2 - figure supplement 2**). Taken together, these results suggest  
200 that most of the ICD residues remain disordered when tethered to the TMD and in the presence of a  
201 neutral membrane mimetic.





202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216

**Fig. 2: The ICJM region of the PRLR interacts with PI(4,5)P<sub>2</sub>.** **A)** Overview of investigated PRLR variants. **B)** Secondary chemical shifts (SCSs) of TMD-ICD<sub>F206-S270</sub> reconstituted in DHPC micelles. **C)** Correlation plot of the SCSs of ICD<sub>G236-Q396</sub> plotted against those of TMD-ICD<sub>F206-S270</sub>. **D)** <sup>15</sup>N,<sup>1</sup>H-HSQC spectra of <sup>15</sup>N-ICD<sub>K235-G313</sub> titrated with 5x, 10x and 25x molar excess of C<sub>8</sub>-PI(4,5)P<sub>2</sub>. **E)** Structure of C<sub>8</sub>-PI(4,5)P<sub>2</sub>. **F)** Backbone amide chemical shift perturbations (CSPs) and peak intensity changes upon addition of C<sub>8</sub>-PI(4,5)P<sub>2</sub> to <sup>15</sup>N-ICD<sub>K235-G313</sub> plotted against residue number. **G)** **Top:** Far-UV CD spectra of Pep1 titrated with C<sub>8</sub>-PI(4,5)P<sub>2</sub> or in 65% TFE. **Middle:** Far-UV CD spectra of Pep1 in the presence of 5x-38x C<sub>8</sub>-PI(4,5)P<sub>2</sub> subtracted with the spectrum of Pep1 in the absence of C<sub>8</sub>-PI(4,5)P<sub>2</sub>. **Bottom:** Far-UV CD spectra of Pep2 titrated with C<sub>8</sub>-PI(4,5)P<sub>2</sub> or in 65% TFE. \* indicate missing data points.

**Figure supplement 1:** <sup>15</sup>N, <sup>1</sup>H-HSQC spectra of A) TMD<sub>F206-V240</sub> and TMD-ICD<sub>F206-S270</sub> in DHPC micelles, and (B) TMD-ICD<sub>F206-S270</sub> in POPC SUVs.

**Figure supplement 2:** C<sup>α</sup> secondary chemical shifts of ICD<sub>G236-Q396</sub>

217 **LID1 binds PI(4,5)P<sub>2</sub> in the juxtamembrane region forming extended structures**

218 PRLR-ICD has previously been shown to bind PI(4,5)P<sub>2</sub> (but not PI(3,4,5)P<sub>3</sub>) (Haxholm et al., 2015),  
219 suggesting that this lipid could modulate membrane affinity and the structural properties of the PRLR-  
220 ICD. To separate headgroup effects from lipid bilayer surface effects, we used a short-chain C<sub>8</sub>-  
221 PI(4,5)P<sub>2</sub>, which has a high critical micelle concentration (CMC) of 2 mM (Goñi et al., 2014) and  
222 analysed the structural changes by NMR and CD spectroscopy at concentrations below the CMC  
223 (Goñi et al., 2014) to identify the binding site.

224  
225 <sup>15</sup>N-labelled ICD<sub>K235-G313</sub> covering LID1 (**Figure 1**) was titrated with C<sub>8</sub>-PI(4,5)P<sub>2</sub> and binding was  
226 assessed by <sup>1</sup>H-<sup>15</sup>N-HSQC spectra (**Figure 2D-F**). The chemical shift perturbations (CSPs) were  
227 modest whereas substantial intensity changes were observed throughout the chain, supporting a direct  
228 interaction between the ICD and lipids. The resonances from G236-F244 completely disappeared  
229 suggesting exchange on an intermediate NMR timescale, while intensities were substantially reduced  
230 in the V247-S290 region (**Figure 2F**). In the region from D285-E292 we observed an almost inverse  
231 correlation between the CSPs and the intensities. This suggests that in contrast to the preceding  
232 region, a faster local exchange rate allows us to follow the resonances from the bound state in this  
233 region, giving rise to the large CSPs. From this region and to the C-terminus, only moderate intensity  
234 changes were observed (**Figure 2F**). These findings suggest that the primary PI(4,5)P<sub>2</sub> binding site  
235 is located closest to the membrane in what we define as the intracellular juxtamembrane (ICJM)  
236 region (K235-C242). The ICJM is located N-terminally to the BOX1 motif (<sub>243</sub>IFPPVPGPK<sub>251</sub>  
237 (UNIPROT); <sub>245</sub>PPVPGPK<sub>251</sub> (elm.eu.org)).

238  
239 As the resonance-broadening precluded observation of the bound state, two overlapping peptides,  
240 Pep1 (K235-D256) and Pep2 (K253-T280), were constructed and evaluated by CD spectroscopy. In  
241 isolation, the peptides were disordered as judged by the negative ellipticity at 200 nm in their far-UV  
242 CD spectra (**Figure 2G**). Pep1 and Pep2 were titrated with C<sub>8</sub>-PI(4,5)P<sub>2</sub> and the structural changes  
243 monitored (**Figure 2G**). For Pep2, the far-UV CD signal was unaffected by the presence of C<sub>8</sub>-  
244 PI(4,5)P<sub>2</sub>. In contrast, for Pep1, large spectral changes were seen, which were unrelated to helix  
245 formation. Subtracting the spectra in the presence and absence of C<sub>8</sub>-PI(4,5)P<sub>2</sub>, revealed a negative  
246 ellipticity minimum at 218 nm, a strong indicator of β-strands, showing that when bound to C<sub>8</sub>-  
247 PI(4,5)P<sub>2</sub>, a distinct extended (strand-like structure) signature was seen (**Figure 2G**). This suggests  
248 that this region of LID1 changes its conformational properties upon binding to C<sub>8</sub>-PI(4,5)P<sub>2</sub>. We  
249 evaluated the intrinsic helical propensities of the two ICD segments by exposure to high  
250 trifluorethanol (TFE) concentrations. Here, Pep2 was readily able to form helical structure as  
251 expected from the presence of two transient helices (Haxholm et al., 2015) (**Figure 2G, top**), whereas  
252 Pep1 was not (**Figure 2G, bottom**).

253  
254 In summary, LID1 of the PRLR-ICD interacts with PI(4,5)P<sub>2</sub>, with the primary interaction site located  
255 in the K235-S290 region. Headgroup interaction was dominantly located to the region K235-D256  
256 constituting the ICJM and the BOX1 motif and this interaction induced the formation of a regional  
257 extended structure in the PRLR-ICD.

258




## 259 **LID1 has specific PI(4,5)P<sub>2</sub> contacts which drive PI(4,5)P<sub>2</sub> recruitment**

260 To obtain a more detailed characterization of the behaviour of the disordered PRLR-ICD near lipid  
261 bilayers, as well as the effect of different anionic lipid headgroups in these, we turned to molecular  
262 simulations. Here, as explained above, we focused on the LID1 (K235-H300), alone and in context  
263 of TMD, and first placed a coarse-grained (CG) model of the TMD-ICD<sub>F206-H300</sub> in three different  
264 mixed-membrane systems. These contained an upper leaflet consisting of 100% POPC and lower  
265 leaflets composed of a 90:5:5 or 80:10:10 mixture of POPC:POPS:PI(4,5)P<sub>2</sub> (**Figure 3AB**) or a 70:30  
266 molar ratio mixture of POPC:1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS) (**Figure**  
267 **3 – figure supplement 1EF**). Since the Martini forcefield may produce unrealistically collapsed  
268 disordered regions, increasing the strength of the protein-water interactions by 8–10% has provided  
269 satisfactory results when applied to the simulation of other disordered regions or multidomain  
270 proteins (Thomassen et al., 2022). Thus, the simulations were run using a modified version of the  
271 Martini3 forcefield with a 10% increase in the strength of the protein-water interactions. For  
272 comparison, similar simulations were performed using the Martini2 forcefield (**Figure 3 – figure**  
273 **supplement 1**).

274  
275 We first analysed the dynamics of the LID1 during the simulations focusing on the pattern of protein-  
276 lipid contacts. Here, we measured the number of protein-lipid contacts focusing either on interactions  
277 between the protein and lipid headgroups or the protein and lipid acyl chains. In both cases we  
278 determined the fraction of the simulation time that the protein and different parts of the lipid were  
279 within 7Å of each other. In general, we observed that residues in the N-terminal part of the LID1  
280 (K235 - D255), which includes the ICJM and BOX1, established contacts with the bilayer in all three  
281 membrane systems (**Figure 3A,B, Figure 3 – figure supplement 2**) Furthermore, a hydrophobic  
282 region rich in prolines (V240–P250) made consistent contacts with the acyl-chains and much more  
283 than to the headgroups, indicating penetration into the lower-leaflet. Similar behaviour has been  
284 reported with CG-MD simulations for the juxtamembrane region of other single-pass transmembrane  
285 receptors (Hedger et al., 2015b). For PRLR, the pattern of interaction was independent on the lipid  
286 composition, at least in terms of protein-POPC contacts, and the region interacting with the lipids  
287 was similar in all three membrane systems (**Figure 3A,B, Figure 3 – figure supplement 2**).

288  
289 Although the extent and pattern of protein-lipid interactions appeared constant, a striking observation  
290 was made in both systems containing PI(4,5)P<sub>2</sub>. Here, protein-lipid interactions between residues  
291 K235 and K253 and PI(4,5)P<sub>2</sub> were present during a large fraction (≥50%) of the simulations, despite  
292 PI(4,5)P<sub>2</sub> being present at only 5% or 10% of the total lipids (**Figures 3 – figure supplement 2**). This  
293 was also observed in simulations with the Martini2 forcefield, in which the LID1 promptly collapsed  
294 in a globular and unstructured coil (**Figure 3 – figure supplement 1**). This suggested that PI(4,5)P<sub>2</sub>  
295 spontaneously accumulated, or in other ways become concentrated around the TMD-ICD<sub>F206-H300</sub>.  
296 The computed average density maps for PI(4,5)P<sub>2</sub> indeed showed that PI(4,5)P<sub>2</sub> formed a  
297 microdomain around the TMD (**Figure 3D**). The low frequency of contacts between the protein and  
298 POPS suggests that POPS did not accumulate or compete with PI(4,5)P<sub>2</sub> for binding to the TMD-  
299 ICD<sub>F206-H300</sub>, further supporting the preference for PI(4,5)P<sub>2</sub> observed earlier (Haxholm et al., 2015).

300 Similar preference was also observed with 5% PI(4,5)P<sub>2</sub> (**Figure 3 – figure supplement 2**) as well as  
 301 with Martini2 (**Figure 3 – figure supplement 2E-F**).  
 302



303  
 304  
 305 **Fig. 3. Protein – lipid interactions of PRLR-ICD<sub>LID1</sub> obtained from CG-MD simulations.** (A-B) Protein – lipid  
 306 contact histograms for PRLR-ICD<sub>LID1</sub> + POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10). **A)** Contacts between the protein and lipid  
 307 headgroups. A contact is counted if the distance between the backbone beads of the protein is  $\leq 7$  Å from the head-group  
 308 beads of the lipids. **B)** Contacts between the protein and the acyl chains of the lipids. A contact is counted if the distance  
 309 between the backbone bead of the protein is  $\leq 7$  Å from the acyl-chain bead of the lipids. **C)** Correlation between the  
 310 change in NMR signal and the contact frequency between PRLR-ICD<sub>LID1</sub> and the lipid headgroups from the PRLR-  
 311 ICD<sub>LID1</sub> + POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) system. Pearson correlation coefficient of -0.55 with  $p = 4.0 \times 10^{-5}$  and  $R^2 =$   
 312 0.3. **D)** Average PI(4,5)P<sub>2</sub> density map (xy-plane) taken from the PRLR-ICD<sub>LID1</sub> + POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10)  
 313 simulation. The map is colored according to the enrichment/depletion percentage with respect to the average density  
 314 value. **E)** Schematic representation of how the interactions and the embedding into the membrane of PRLR contribute to  
 315 the co-structure formation. The data from the simulations correspond to those of the production stage (see methods).  
 316

317 **Figure supplement 1: Protein – lipid interactions of PRLR-ICD<sub>LID1</sub> obtained from CG-MD simulations using the martini**  
 318 **3.0b3.2 forcefield**

319 **Figure supplement 2:** Complementary analysis of the Protein – lipid interactions of PRLR-ICD<sub>LID1</sub> obtained from CG-  
320 MD simulations.

321

322 A more detailed analysis of LID1-PI(4,5)P<sub>2</sub> contacts revealed a preference for certain residues, shown  
323 as peaks in the protein-headgroup contact profiles. In particular K235, S238, T241, and K251 and  
324 K253, which define a KIK motif suggested as a PI(4,5)P<sub>2</sub> binding motif (Kjaergaard and Kragelund,  
325 2017), engaged in highly populated contacts (**Figure 3A and figure supplement 2A**). The pattern of  
326 contacts was not affected by PI(4,5)P<sub>2</sub> concentration; however, the frequency of contacts almost  
327 doubled as a result of the increase from 5% to 10% of PI(4,5)P<sub>2</sub>. The hydrophobic residues in the  
328 ICJM and BOX1 penetrate the headgroup layer and facilitate the approximation of the KIK motif to  
329 the PI(4,5)P<sub>2</sub> headgroups. The stabilization of the structure provided by the hydrophobic residues  
330 from the ICJM and BOX1 is also reflected in their decrease in flexibility, observed as a shoulder on  
331 the RMSF-BB plot, for the residues that comprise the ICJM and BOX1 of PRLR-LID1. Very similar  
332 profiles of the RMSF-BB plot was obtained for the systems with respectively 5 and 10% PI(4,5)P<sub>2</sub> in  
333 POPC:POPS, suggesting that the loss in flexibility is coupled to the buried hydrophobic residues  
334 rather than to specific PI(4,5)P<sub>2</sub> interaction (**Figure 3 – figure supplement 2C**). Contributions from  
335 other positively charged residues such as K262 and K264 were very small. To validate the  
336 observations from the simulations, we compared the pattern of protein:PI(4,5)P<sub>2</sub> interactions  
337 observed in the NMR experiments to those from the simulations containing PI(4,5)P<sub>2</sub> (**Figure 3C**).  
338 A clear correlation between loss of NMR signal and high frequency of protein-PI(4,5)P<sub>2</sub> and  
339 POPC/POPS contacts in the 80:10:10 simulation was observed, reinforcing that the simulations are  
340 able to capture the specificity of protein-PI(4,5)P<sub>2</sub> interactions. Furthermore, both experiments  
341 (**Figure 2**) and simulations (**Figure 3**) show that the residues involved in binding to PI(4,5)P<sub>2</sub>-  
342 containing membranes overlap with those that are involved in binding to JAK2.

343

344 In summary, the CG-simulations of TMD-ICD<sub>F206-H300</sub> near lipid membranes showed accumulation  
345 of PI(4,5)P<sub>2</sub> around the TMD and the N-terminus of LID1 involving the ICJM and BOX1. The  
346 residues made contact with the membrane independently of lipid type, with BOX1 residues acting as  
347 a tether by penetrating the headgroups. This tethering keeps positively charged residues, such as K251  
348 and K253, near the membrane. This may be the driver for PI(4,5)P<sub>2</sub> recruitment, enhanced by higher  
349 PI(4,5)P<sub>2</sub> concentration. Intriguingly, we observed that the same regions involved in JAK2 binding  
350 (BOX1), also play roles in membrane association and lipid recruitment.

351

### 352 **JAK2-FERM-SH2 and PRLR-ICD<sub>LID1</sub> form co-structures with PI(4,5)P<sub>2</sub> on membranes**


353 It has been suggested that JAK2 and PRLR interact constitutively in cells (Campbell et al., 1994; Rui  
354 et al., 1994) although recent data for the GHR have shown that the Src family kinase Lyn competes  
355 for this site (Chhabra et al., 2023). Thus, given our observations that residues from LID1 form lipid-  
356 specific contacts with the membrane constituents using the same region covering the binding interface  
357 with the FERM domain of JAK2, we decided to explore the structure and dynamics of the  
358 JAK2(FERM-SH2):PRLR(LID1) complex near lipid bilayers (**Figure 4**). To do so, an atomistic  
359 model of the complex of a smaller region of PRLR-ICD<sub>K235-E284</sub> bound to the JAK2-FERM-SH2  
360 domains (residues P37 to T514) was built, taking advantage of crystal structures of JAK2-FERM-

361 SH2 and of JAK1-FERM-SH2 and TYK2-FERM-SH2 bound to analogous fragments of the ICDs of  
362 the interferon  $\lambda$ - and  $\alpha$ -receptors (IFNLR1 and IFNAR1), respectively. This model was used to  
363 perform all-atom MD simulations in a water-box to obtain equilibrated structures for further  
364 simulations, and to study the dynamics of the protein complex. The average contact map between  
365 JAK2-FERM-SH2<sub>P37-T514</sub> and PRLR-ICD<sub>K235-E284</sub> showed clusters of contacts in which residues from  
366 BOX1 of LID1 formed close contacts (avg. dist.  $\leq 4\text{\AA}$ ) with residues from the F2 lobe (and the F1-  
367 F2 linker) and the SH2 domain of JAK2-FERM-SH2, respectively (**Figure 4 – figure supplement**  
368 **1A**). C-terminally to BOX1, a second set of persistent contacts was observed, again involving charged  
369 and hydrophobic residues including F255, L259, E261, K262 and K264 from PRLR-ICD<sub>K235-E284</sub>.  
370 Conservation analysis using ConSurf (Ashkenazy et al., 2016; Landau et al., 2005) (**Figure 4 – figure**  
371 **supplement 1B-D**) showed conserved residues in the interface, particularly those of BOX1 of PRLR  
372 (P245, P248, K251, I252) (**Figure 4 – figure supplement 1B**), while a patch of conserved residues  
373 (T225, I229 and F236) in JAK2-FERM-SH2 formed close contact with residues from PRLR BOX1.  
374 JAK2 residues V183 and L184 interacted with the backbone of <sub>251</sub>KIK<sub>253</sub> of PRLR-ICD, whereas  
375 other, less conserved residues such as E173 and E177 formed transient salt-bridges with K251 and  
376 K253 of PRLR-ICD (see **Figure 4 – figure supplement 1A**). The contact map also showed that the  
377 N-terminus of the ICJM remained flexible without close contacts with JAK2-FERM-SH2 (avg. dist.  
378  $\geq 6\text{\AA}$ ).

379  
380 Next, an equilibrated structure of the JAK2-FERM-SH2:PRLR-ICD<sub>K235-E284</sub> complex was used to  
381 build a coarse-grained model, which was then placed near lipid bilayers of different lower leaflet  
382 composition. A number of randomly positioned starting orientations were placed  $\sim 7\text{\AA}$  below the  
383 lower leaflet (16 orientations for the POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) membrane and eight for the  
384 POPC:POPS (70:30) membrane). In addition we included twelve orientations of JAK-FERM-SH2  
385 without the PRLR-ICD<sub>K235-E284</sub> placed near a POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) membrane. For the  
386 JAK2-FERM-SH2:PRLR-ICD<sub>K235-E284</sub> complex near a 70:30 POPC:POPS membrane, binding to the  
387 lower leaflet was observed for only three of the eight systems (**Figure 4 – figure supplement 2A**). In  
388 contrast, when PI(4,5)P<sub>2</sub> was present (10%), rapid binding of the complex to the membrane was  
389 observed in all simulations reaching 97% saturation (**Figure 4 – figure supplement 2A**). Both  
390 proteins in the complex showed specific clusters of residues with contacts to PI(4,5)P<sub>2</sub>, POPS and  
391 POPC, independent of the initial orientations (**Figure 4BC**). The number of contacts formed was  
392 higher for the simulations with PI(4,5)P<sub>2</sub>. This suggests that contacts with other components of the  
393 membrane occur close to the bound PI(4,5)P<sub>2</sub>. Overall, the PRLR-ICD<sub>K235-E284</sub> showed a pattern of  
394 lipid contacts similar to the simulations of PRLR TMD-ICD<sub>G204-H300</sub> with the POPC:POPS:PI(4,5)P<sub>2</sub>  
395 (80:10:10) membrane (**Figure 4C**), with residues K<sub>235</sub>GY<sub>237</sub> contacting PI(4,5)P<sub>2</sub> headgroups for at  
396 least 50% of the total contact time and with insertion into the membrane; note that this occurs even  
397 though PRLR-ICD<sub>K235-E284</sub> is not tethered to the membrane via the TMD. Also, like in the PRLR  
398 TMD-ICD<sub>G204-H300</sub> simulations, contacts made by C242 and I243 to POPC were still present. In  
399 contrast, contacts by other residues from BOX1 and the KIK motif has lower populations. However,  
400 and as expected from the location of the most frequent PRLR-ICD<sub>K235-E284</sub>/lipid contacts, JAK2-  
401 FERM-SH2 had more contacts in the F2 lobe of the FERM domain, mainly involving residues I223,  
402 L224, R226, K227 and R230, constituting the regions where the N-terminus of PRLR-ICD<sub>K235-E284</sub> is



403 bound (**Figure 4B**). In the JAK2-FERM-SH2 simulations without PRLR-ICD and near a  
 404 POPC:POPS:PI(4,5)P<sub>2</sub> (80:80:10) membrane, we observed that simulations initiated in eleven out of  
 405 the twelve orientations ended up binding to the membrane (**Figure 4 – figure supplement 2A**). In this  
 406 case, the overall binding pattern of protein-lipid contacts remained similar.  
 407



408

409 **Fig. 4. Protein – lipid interactions of the JAK2-FERM-SH2 PRLR-ICD<sub>LID1</sub> complex obtained from CG-MD**  
410 **simulations. A)** Schematic representation of the simulated system. Combined **B) JAK2-FERM-SH2-lipid** and **C) PRLR-**  
411 **ICD<sub>LID1</sub>-lipid** contact frequency histograms for the 16 CG simulations of the JAK2-FERM-SH2 +PRLR-ICD<sub>LID1</sub>+  
412 **POPC:POPS:PI(4,5)P<sub>2</sub>** system. **D)** Distribution of the orientations adopted by the JAK2-FERM-SH2 + PRLR-ICD<sub>LID1</sub>  
413 complex when bound to lipids taken from the 16 simulations with POPC:POPS:PI(4,5)P<sub>2</sub> in the lower-leaflet. The  
414 snapshots surrounding the map correspond to representative conformations of the highlighted states also indicating the  
415 fraction total bound time for which each state was observed. Representative conformations of **E) State 2** and **F) State 4**.  
416 The grey cylinder depicts the position where PRLR-TMD should be located. Representative protein-lipid contact  
417 histograms for **G) State2** and **H) State4** colored as in panels B and C.

418 **Figure supplement 1:** *Analysis of the JAK2-FERM-SH2- PRLR-ICD<sub>LID1</sub> AA-MD simulation.*

419 **Figure supplement 2.** *Complementary analysis of Protein – lipid interactions of the JAK2-FERM-SH2 PRLR-ICD<sub>LID1</sub>*  
420 *complex obtained from CG-MD simulations*

421 **Figure supplement 3.** *Snapshots of the different binding states observed for the JAK2-FERM-SH2 – PRLR-ICD<sub>LID1</sub>*  
422 *complex with the complete structural model of JAK2*

423

424 Previous studies have suggested that the Martini2 forcefield model underestimates cation- $\pi$   
425 interactions between surface aromatic residues and choline headgroups on the membrane (Khan et  
426 al., 2020). However, this may not be applicable to other types of protein-membrane interactions,  
427 particularly where negatively charged headgroups are present. Our simulations involving PI(4,5)P<sub>2</sub>  
428 and POPS suggest that interactions between PRLR and the bilayer are primarily driven by positively  
429 charged residues in the protein, and that other protein-membrane interactions are secondary or occur  
430 between the lipids and residues that surround positively charged residues interacting with a PI(4,5)P<sub>2</sub>  
431 (or POPS) lipid. As a result, cation- $\pi$  interactions may not be as important for the protein-lipid contact  
432 patterns we observed, but could be one explanation as to why we observe less frequent binding in the  
433 POPC:POPS systems.

434

435 In summary, our simulations showed that binding of JAK2 to the membrane was enhanced by the  
436 presence of PI(4,5)P<sub>2</sub> and that the ICD from PRLR and JAK2 formed a co-structure with PI(4,5)P<sub>2</sub>  
437 maintaining the contacts to the lipids observed for the individual proteins. The presence of PI(4,5)P<sub>2</sub>  
438 was essential for the membrane interactions.

439

440 **The complex between JAK2-FERM-SH2 and LID1 shows preferential bound orientations with**  
441 **membranes containing PI(4,5)P<sub>2</sub>**

442 To characterize the membrane-bound modes of the complex in more detail, we took inspiration from  
443 Vogel *et al.* (Herzog et al., 2017) and constructed a map that represents the populations of different  
444 orientations of the JAK2-PRLR-ICD<sub>K235-E284</sub> complex relative to the membrane and extracted  
445 conformations to represent the most populated orientations as classified into states (**Figure 4D**). For  
446 the JAK2-PRLR-ICD<sub>K235-E284</sub> complex bound to the POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) membrane,  
447 States 1–4 (~31% of the total contact time) showed the complex in an orientation where the N-  
448 terminus of PRLR-ICD<sub>K235-E284</sub> contacted and inserted into the bilayer similarly to what was observed  
449 in the PRLR TMD-ICD<sub>G204-H300</sub> simulations near a POPC:POPS:PI(4,5)P<sub>2</sub> bilayer. Of these four  
450 states, States 1, 2 and 3 had the F2 lobe of the JAK2-FERM domain and the ICJM region of PRLR-  
451 ICD<sub>K235-E284</sub> in contact with the membrane, penetrating below the headgroups, and acting as a pivot  
452 over which the protein-complex rotates, leaving the complex to hang as a “Y” from the membrane



453 (See **Figure 4DE** and **MOVIE1**). State 4 on the other hand, while retaining the main contact points,  
454 assumed a “flat” orientation with larger sections of the F2 lobe and F1-F2 linker from JAK2-FERM  
455 and the entire N-terminal half of PRLR-ICD<sub>K235-E284</sub> (residues K235-G263) making a substantial  
456 number of contacts with the membrane (**Figure 4DF** and **MOVIE2**). To examine whether the  
457 identified states are compatible with functional states of the full-length kinase, we superimposed  
458 representative conformations of States 1 to 6 with that of the full-length JAK2 model obtained from  
459 the AlphaFold Protein Structure Database (UNIPROT O60674) (Jumper et al., 2021; Varadi et al.,  
460 2022). This procedure revealed that both the Y (States 1, 2 and 3), and Flat (State 4) states keep the  
461 other domains of JAK2 oriented towards the cytoplasmic space (**Figure 4 – figure supplement 3AD**),  
462 supporting that these states could be functionally relevant. Furthermore, in the context of JAK2  
463 dimerization required for signalling (Ferrao et al., 2018), these states allow for the correct orientation  
464 for kinase domain dimerization. The two remaining states (States 5 and 6) showed an inverted  
465 orientation in which the main protein-lipid interactions were formed by residues from the F3 lobe of  
466 FERM and the SH2 domain, bringing the F2 lobe and the ICJM region of the PRLR-ICD  
467 unrealistically far away from the membrane and from the connecting end of the TMD. Thus, States 5  
468 and 6 appear functionally irrelevant, as further demonstrated by the superposition of the full-length  
469 AlphaFold model of JAK2 in which the kinase domains would clash with the bilayer (**Figure 4 –**  
470 **figure supplement 3EF**).

471

#### 472 **Different membrane co-structures have different exposures relevant to signalling**

473 We analysed the protein-lipid interactions formed by States 2 (Y) and 4 (Flat) in more detail, and  
474 despite overall similar contact profiles, some key differences were observed (**Figure 4E–4H**). For  
475 the Flat state, an increase in contacts was seen for residues K235 to L260 of PRLR-ICD<sub>K235-E284</sub> with  
476 a pattern similar to the one observed in the PRLR-TMD-ICD<sub>G204-H300</sub> simulations with PI(4,5)P<sub>2</sub>  
477 present. Dominant PI(4,5)P<sub>2</sub> contacts were seen for K235–C242, followed by POPC contacts for  
478 residues C242–P248, with a second PI(4,5)P<sub>2</sub> contact peak for K251 and a third around H257. For  
479 the Y state, only residues K235–Y237 made substantial contacts with PI(4,5)P<sub>2</sub> and/or POPC, leaving  
480 BOX1 and the KIK motif exposed to the solvent and making contacts with JAK2. For JAK2-FERM-  
481 SH2, the main difference between the Y and Flat states was a large decrease in contacts to the F2  
482 lobe in the Flat state accompanied by an increase in contacts in F3 and SH2. Residues in the F2 lobe  
483 involved in homodimerization, orientation and activation, including L224, K227, R230 and R234  
484 (Wilmes et al., 2020) were only accessible in the Y state, and not in the Flat state. Thus, we speculate  
485 that the Y and Flat states may mimic functionally relevant conformations pertaining to active and  
486 inactive states of the signalling complex. Mapping of residues that make contacts with the bilayer in  
487 the two states to the conservation maps shows that several positively charged residues of JAK2-  
488 FERM-SH2 are largely conserved. Particularly K207, R226, K227 and R228 in F2 with high  
489 population contacts with PI(4,5)P<sub>2</sub> in the Y state are highly conserved. Similar conservation was seen  
490 for the positively charged residues K235, K414, K415 and R513, that form contacts with PI(4,5)P<sub>2</sub> in  
491 the Flat state.

492

493 Similar simulations were performed near a POPC:POPS 70:30 bilayer, which resulted in only one of  
494 eight systems showing stable binding to the bilayer characterized by only one state (**Figure 4 – figure**


495 **supplement 2A,B**). Here, residues from the F2 lobe of JAK2 form contacts with POPS lipids in a  
496 narrow peak containing residues Q219 to R230, while for PRLR-ICD<sub>K235-E284</sub>, residues from the  
497 ICJM (K235-C242) and the BOX1 region (C242-P248), make high frequency contacts with both  
498 POPS and POPC (**Figure 4 – figure supplement 2DE**). Overall this state is somewhat similar to State  
499 3 observed for the simulations with PI(4,5)P<sub>2</sub>. Similarly, for our simulations of JAK2-FERM-SH2  
500 without PRLR near a bilayer with PI(4,5)P<sub>2</sub>, 11 out of 12 stable binding conformations revealed three  
501 most populated states (E1, E2, E3) (**Figure 4 – figure supplement 2C**). Characterization of these in  
502 terms of protein-lipid contact profiles revealed that the positively charged residues in the F2 lobe play  
503 an important role in binding to PI(4,5)P<sub>2</sub> in a similar manner as observed for the Y and Flat states of  
504 the complex (**Figure 4 – figure supplement 2F**). Indeed, States 2 and 3 (**Figure 4 – figure supplement**  
505 **2GH**) show remarkable similarities with the Flat and Y state from the simulations of the JAK2-  
506 FERM-SH2:PRLR-ICD<sub>K235-E284</sub> complex near a similar bilayer.

507  
508 Overall, the simulations highlight preferential binding of both JAK2-FERM-SH2, both alone and in  
509 complex with PRLR-ICD<sub>K235-E284</sub> to PI(4,5)P<sub>2</sub>, and show that the absence of this lipid decreases the  
510 level of LID1 binding to the bilayer. Even in the absence of TMD tethering, the most populated bound  
511 states recapitulate the binding mode observed for the PRLR-ICD alone. Another key observation is  
512 the existence of different states in which different regions of both JAK2 FERM-SH2 domain and  
513 LID1 of PRLR are exposed to the solvent or hidden below the bilayer.

#### 514 515 **Key residues for membrane interaction control cellular signalling efficiency**

516 From the NMR experiments and MD simulations we identified residues in LID1 that interact with  
517 different components of the membrane and/or the FERM-SH2 domain of JAK2. This resulted in four  
518 clusters positioned in the ICJM (K235-C242), the BOX1 region (C242–P248), two basic patches of  
519 the KxK motif type (K251–K253 and K262–K264) and hydrophobic residues in the region  
520 connecting them, respectively. To decipher the specific role of these clusters for PI(4,5)P<sub>2</sub> interaction,  
521 we introduced four sets of mutations in ICD<sub>K235-G313</sub> and investigated the effect on PI(4,5)P<sub>2</sub>  
522 interaction using NMR spectroscopy. Based on the NMR data and simulations, we focused on the  
523 KxK motifs, which would be involved in binding to PI(4,5)P<sub>2</sub> (**Figure 3A**) and JAK2 (**Figure 4 –**  
524 **supplement figure 1**), the CIF sequence, indicated to be important to membrane binding (**Figures 2**  
525 **and 3B**) and four hydrophobic residues, where at least two were seen to be important for JAK2  
526 binding (**Figure 4- supplement figure 1**). We avoided interfering directly with the BOX1 core motif  
527 (P245–P250) (Pezet et al., 1997). Thus, the CIF motif (C242–F244) was mutated to GAG (GAG  
528 mutant: C242G, I243A, F244G), while the lysines in the KxK motifs (251–253 and 262–264) were  
529 all mutated to either glycines (K4G mutant: K251G, K253G, K262G, K264G) or, for charge reversal,  
530 to glutamates (K4E mutant: K251E, K253E, K262E, K264E). Finally, four hydrophobic residues  
531 (I<sub>252</sub>, F<sub>255</sub>, L<sub>259</sub> and L<sub>260</sub>) were mutated to glycines ( $\phi$ 4G mutant). <sup>15</sup>N-PRLR-ICD<sub>K235-G313</sub> and the four  
532 variants were titrated with up to 25× molar excess of C<sub>8</sub>-PI(4,5)P<sub>2</sub>, keeping the concentration below  
533 the CMC. <sup>1</sup>H-<sup>15</sup>N-HSQC spectra were recorded at each titration point and the changes in chemical  
534 shifts and signal intensities were quantified (**Figure 5A**). Similarly to WT, all variants showed  
535 negligible chemical shift changes (**Figure 5 – figure supplement 1**) but large peak intensity changes.  
536 Decreased peak intensities were observed for all variants in the region of G236-D295, where the

537 changes were largest for the  $\phi$ 4G mutant and K4G, and similar to WT, while smaller effects were  
 538 seen for the GAG and the K4E variants, suggesting weaker affinities. Together, this indicates that the  
 539 KxK motifs and the CIF-motif are involved in PI(4,5)P<sub>2</sub> interaction, as expected from the contacts  
 540 predicted from simulation and NMR and CD data, yet none of these residues are essential for binding.  
 541



542

543 **Fig. 5. PRLR variants with mutations in lipid interacting residues exhibit decreased PRL-stimulated STAT5**  
544 **activation in AP1-2PH-PLC $\delta$ -GFP cells. A)** NMR intensity changes of ICD<sub>K235-G313</sub> WT, K4G, K4E,  $\phi$ 4G and GAG  
545 variants upon titration with 5x, 10x and 25x molar excess C<sub>8</sub>-PI(4,5)P<sub>2</sub> plotted against residue number. **B)** The PRLR  
546 variants (WT, K4G, K4E,  $\phi$ 4G, GAG) were transiently transfected in AP1 cells stably expressing the 2PH-PLC $\delta$ -GFP  
547 construct which visualizes the plasma membrane by binding PI(4,5)P<sub>2</sub>. The cells were subsequently analysed by  
548 immunofluorescence microscopy, using antibodies against PRLR (magenta) and GFP (green), as well as DAPI (blue) to  
549 mark nuclei. To the right, examples of an average line-scan for each PRLR variant is shown. The fluorescence intensity  
550 depicted along the white line drawn (arrow) and green fluorescence (plasma membrane) was used to divide the line in a  
551 plasma membrane section and intracellular section, and relative membrane localization was calculated as the average  
552 fluorescence of PRLR in the membrane section divided by that in the intracellular section. **C, D)** AP1-2PH-PLC $\delta$ -GFP  
553 cells were transiently transfected with PRLR variants (WT, K4G, K4E,  $\phi$ 4G, GAG, K2E<sub>253</sub>, K2E<sub>261</sub>) and incubated  
554 overnight followed by serum starvation for 16-17 h and were subsequently incubated with or without 10 nM prolactin for  
555 30 min. The resulting lysates were analysed by western blot for STAT5, pSTAT5 (Y964), PRLR,  $\beta$ -actin and p150 levels.  
556 The immunoblots are representative of three biological replicates. **E)** Ratio of plasma membrane localized receptor  
557 compared to intracellular receptor, analysed by line-scans as in B. Each point represents an individual cell, and data are  
558 based on three independent biological experiments per condition. Graphs show means with SEM error bars. \*P<0.05,  
559 \*\*P<0.01 and \*\*\*\*P<0.0001. One-way ANOVA compared to WT, unpaired. **F)** Quantification of western blot results  
560 shown as pSTAT5 normalized to total STAT5, relative to the WT condition. Graphs show means with SEM error bars.  
561 \*P<0.05 and \*\*P<0.01. One-way ANOVA compared to WT, unpaired.

562 **Source file 1:** Raw western blots (relating to *figure 5C*)

563 **Source file 2:** Raw western blot (relating to *figure 5D*)

564 **Source file 3:** Data summaries (relating to *figure 5E,F*)

565 **Figure supplement 1:** *Chemical shift perturbations of ICD<sub>K235-G313</sub> of A) WT, B) K4E, C) GAG, D) K4G and E)  $\phi$ 4G*  
566 *variants.*

567 **Figure supplement 2:** *<sup>15</sup>N R<sub>2</sub> relaxation rates of ICD<sub>K235-G313</sub> of WT (grey bars), K4G (blue dots) and  $\phi$ 4G (red*  
568 *squares) variants.*

569  
570 We observed dramatic increases in peak intensities for the K4G and  $\phi$ 4G variants in the presence of  
571 5 $\times$  and 10 $\times$  molar excess of C<sub>8</sub>-PI(4,5)P<sub>2</sub> when compared to WT (**Figure 5A**), suggesting changes in  
572 the dynamics of the chain. To address this, we probed the backbone dynamics by acquiring <sup>15</sup>N R<sub>2</sub>  
573 relaxation rates of the WT, K4G and  $\phi$ 4G variants in the absence of C<sub>8</sub>-PI(4,5)P<sub>2</sub> (**Figure 5 – figure**  
574 **supplement 2**). Compared to the WT, no major changes in R<sub>2</sub> were observed for two variants. The  
575 intensity increase observed for the K4G and  $\phi$ 4G variants during the titration with C<sub>8</sub>-PI(4,5)P<sub>2</sub>  
576 therefore indicates increased backbone dynamics upon binding to C<sub>8</sub>-PI(4,5)P<sub>2</sub> compared to the WT.  
577 Although we cannot explain this observation, it suggests that binding to C<sub>8</sub>-PI(4,5)P<sub>2</sub> increases the  
578 dynamics of the first parts of the chain and thus require higher concentration of C<sub>8</sub>-PI(4,5)P<sub>2</sub> to fully  
579 form the complex, as expected by the lower apparent affinity.

580  
581 To address the implications of PI(4,5)P<sub>2</sub> interaction for PRLR membrane localization and  
582 downstream signalling, and to enable a potential separation of effect of perturbed membrane  
583 localization from direct PI(4,5)P<sub>2</sub> binding, we introduced the same four sets of mutations into the full-  
584 length PRLR. Together with WT PRLR, these were transiently transfected into AP1 mammalian  
585 epithelial cells, which were stably transfected with the fluorescent PI(4,5)P<sub>2</sub> reporter 2PH-PLC $\delta$ -  
586 GFP. The cells were subjected to fluorescence microscopy analysis of PRLR and the PI(4,5)P<sub>2</sub>  
587 reporter (Fig. 5B) and to western blot analysis of STAT5-activating phosphorylation (**Figures 5C-D,**  
588 **F-G**). None of the mutations fully abolished PRLR membrane localization. Western blot analysis



589 showed that the protein expression levels were similar for WT PRLR and all PRLR variants (**Figure**  
590 **5C**). However, compared to WT, the K4G, K4E and  $\phi$ 4G variants exhibited a significant reduction  
591 in membrane localization as determined by line scan analysis (**Figures 5B,E**). This is in accordance  
592 with their predicted JAK2 contacts obtained from the simulations, as JAK2 is known to be important  
593 for PRLR trafficking (Huang et al., 2001). The PRL-induced STAT5 activation was significantly  
594 decreased in cells expressing either the K4G, K4E or the  $\phi$ 4G variants, whereas STAT5 activation in  
595 cells expressing the GAG variant was not significantly different from that of WT expressing cells  
596 (**Figures 5C,F**). Decomposing the K4E variant into two individual mutants, in which only one of the  
597 two KxK motifs was changed (K2E<sub>251</sub> and K2E<sub>262</sub>) showed that the reduction in STAT5 activation  
598 was attenuated in the variants with the individual mutations, compared to the drastic decrease  
599 observed for the K4E mutant (**Figure 5D,G**). Thus, both KxK motifs are important for JAK/STAT  
600 activation, which suggests that both PI(4,5)P<sub>2</sub> and JAK2 binding are important in this regard.

601  
602 Taken together, these results show that while our data are consistent with the decreased membrane  
603 localization contributing to the reduction of STAT5 activation, it is unlikely to account fully for the  
604 effect observed for the K4G, K4E or the  $\phi$ 4G variants. Part of this reflects impaired binding to JAK2,  
605 known to affect the amount of receptor at the cellular membrane. The MD simulations indicated that  
606 only the first KxK motif is involved in lipid interaction while the second KxK motif is involved in  
607 JAK2 interaction. Thus, a part of the the reduction in JAK/STAT activation in these variants could  
608 arise from a combined effect of abolishing both PI(4,5)P<sub>2</sub>- and JAK2 interaction within the LID1  
609 region, which support the suggestion that co-structure formation between JAK2, PRLR and the  
610 membrane is critical for optimal JAK/STAT signalling. However, within this co-structure, the  
611 involved residues will likely affect several binding events, and thus separation of function by selective  
612 mutations may not be straightforward.

613


## 614 **Discussion**

615 The sequence of the human PRLR has been known for more than 35 years (Boutin et al., 1988). Little  
616 attention has, however, been given to the role of membrane composition for PRLR signalling, despite  
617 it being placed in the plasma membrane where phosphoinositide levels are highly dynamic and  
618 spatially variable, and being linked to cancer with lipid deregulation (Dadhich and Kapoor, 2022).  
619 Here we asked if JAK2 and PRLR-ICD share a PI(4,5)P<sub>2</sub> binding site and if and how the binding to  
620 PI(4,5)P<sub>2</sub> plays a role in the orientation of these proteins with respect to the membrane. Integrating  
621 MD simulations with biophysical and cellular experiments has been critical in this endeavor. Our first  
622 goal was to identify the residues of LID1 involved, as well as the structure formed—if any—in the  
623 protein–lipid complex. Our results suggest that the residues that form the ICJM and BOX1 regions  
624 of the ICD interact with the lipids via non-specific hydrophobic interactions that involve penetration  
625 of the bilayer below the headgroups. This in turn enables positively charged residues of the <sub>251</sub>KIK<sub>253</sub>  
626 motif to establish ionic interactions with PI(4,5)P<sub>2</sub> and in doing so the region folds into an extended  
627 structure, similar to structures of other cytokine receptors in complex with either JAK1 or TYK2  
628 (Wallweber et al., 2014; Zhang et al., 2016). In turn, PI(4,5)P<sub>2</sub> lipids accumulate around the TMD  
629 and LID1 of PRLR, suggesting a relevant functional role of the interaction.

630

631 The results highlight the capacity of the LID1 to establish highly populated and specific interactions  
632 with PI(4,5)P<sub>2</sub> via residues essential for its interaction with JAK2. Therefore, we addressed whether  
633 LID1 in complex with the FERM-SH2 domain of JAK2 could engage with the lipid bilayer in the  
634 absence of the TMD and with or without PI(4,5)P<sub>2</sub> lipids. Indeed, PI(4,5)P<sub>2</sub> was required for binding  
635 of the complex to the membrane, as the presence of only POPS in the lower leaflet was not enough  
636 to sustain binding despite its negative charge. Remarkably, when PI(4,5)P<sub>2</sub> was present, we observed  
637 specific binding orientations that positioned the ICJM region of the LID1 in the same position as  
638 when tethered to the TMD. Furthermore, in the complex, the protein-lipid contact profiles were  
639 similar to the one observed for LID1 alone suggesting the PI(4,5)P<sub>2</sub> binding pattern to be maintained  
640 in complex with JAK2. A detailed study of two of the most populated PRLR-bound states of JAK2  
641 revealed a striking difference in orientation and contact pattern with the lipids, that could shed light  
642 on functionally relevant states. For example, the most populated state, the Y state, had contacts from  
643 the F2 lobe of the JAK2-FERM-SH2 domain and the ICJM of the PRLR, which penetrated the  
644 membrane forming hydrophobic interactions with the acyl chains. In this orientation, regions of both  
645 JAK2 and the PRLR that have been associated with receptor dimerization and activation for signaling  
646 (Ferrao et al., 2018; Wilmes et al., 2020) are exposed to solvent and available for interactions. We  
647 note that this orientation has resemblance to that shown in recent cryoEM structures of JAK1 bound  
648 to IFNAR1 (Glassman et al., 2022). For the Flat state, we observed a drastic change in the protein-  
649 lipid contact profiles for both proteins, but more markedly for LID1. While the main interaction site  
650 remains the F2 lobe of JAK2 and the ICJM of the PRLR, the N-terminal residues of the LID1 now  
651 lie sandwiched between the membrane and JAK2-FERM-SH2 domain and recapitulates the binding  
652 pattern observed from TMD-ICD<sub>F206-H300</sub> simulations with membranes containing PI(4,5)P<sub>2</sub>.  
653 Remarkably, in this Flat state, most of the accessible regions in the Y states are now hidden under the  
654 membrane. Thus, we speculate that the Y and Flat states may mimic an available and hidden state,  
655 respectively, that could be relevant for regulation of dimerization and activation of signaling.  
656 Interestingly, one residue that has been suggested to play a major role in JAK2 membrane association,  
657 orientation, dimerization, and activation is L224 (Wilmes et al., 2020). This residue anchors into the  
658 membrane only in the Y-state, and not in the Flat-state. Similarly, in simulations where L224 was  
659 mutated to glutamate, a change in preferred orientation together with loss of dimerization and JAK2  
660 and STAT5 phosphorylation was observed (Wilmes et al., 2020). This further highlight that the  
661 orientation of the PRLR-JAK2 complex relative to the membrane has functional relevance.  
662 Importantly, the presence of PI(4,5)P<sub>2</sub> in the membrane structurally tightens the path from the ECD,  
663 folding the ICJM and BOX1 in an extended structure, making transmission of information of  
664 hormone binding possible. Thus, signal relay by disordered linker of the PRLR can now be possible  
665 through its complex formation with the membrane and JAK2 (*Figure 6*).  
666





667  
668 **Fig. 6. Model of how co-structure formation between JAK2, PRLR and PI4(4,5)P<sub>2</sub> may contribute to signalling**  
669 **fidelity.** The suggested states in signalling would be **A)** the inactive state of the co-structure exemplified by the Flat  
670 orientation. **B)** The hormone bound state exemplified by the co-structure in the Y orientation. **C)** Phosphorylation of  
671 PI(4,5)P<sub>2</sub> to PI(3,4,5)P<sub>3</sub> for which the PRLR has no affinity may lead to downregulation and/or termination of signalling.  
672 The colour scheme of the proteins is identical to Fig.4.  
673

674 Lastly, we tested the functional relevance of our observations by mutating residues that appeared  
675 significant for PI(4,5)P<sub>2</sub>:PRLR:JAK2 co-structure formation and determining their impact on cellular  
676 PRL signaling. Both KxK motifs and the hydrophobic residues connecting them were important for  
677 PI(4,5)P<sub>2</sub> interaction, PRLR membrane localization and cellular JAK2/STAT5 signaling. From the  
678 MD simulation it was however evident that not all residues in these motifs were in direct contact with  
679 the membrane, further highlighting that co-structure formation between PRLR, JAK2 and the  
680 membrane is essential for optimal signal transduction. Another interesting observation was that even  
681 though mutating the CIF motif had the largest impact on PI(4,5)P<sub>2</sub> binding, it had only a limited effect  
682 on cellular JAK2/STAT5 signaling. Since the NMR results suggested that the ICJM serves as a  
683 primary PI(4,5)P<sub>2</sub> anchoring point facilitating additional contacts along the chain, this could indicate  
684 that a cooperative interaction within the co-structure is needed to control signaling and that PI(4,5)P<sub>2</sub>  
685 interaction is necessary for proper and substantial co-structure formation.  
686

687 The PI(4,5)P<sub>2</sub>-specific interactions observed point toward a possible regulatory role of PI(4,5)P<sub>2</sub> in  
688 PRLR signaling. Our simulations showed that the membrane embedded TMD-ICD<sub>F206-H300</sub> was  
689 associated with an accumulation of PI(4,5)P<sub>2</sub> around the TMD. One of the suggested roles of  
690 PI(4,5)P<sub>2</sub> as a regulatory lipid is indeed to form microdomains around proteins and reduce their lateral  
691 movement (Trimble and Grinstein, 2015; van den Bogaart et al., 2011). Another possible role can be  
692 inferred from previous studies on the EGFR. Evidence suggests a positive feedback loop where  
693 inhibition is released upon activation, because PI(4,5)P<sub>2</sub> is hydrolyzed to DAG and IP<sub>3</sub> by PLC<sub>γ</sub>  
694 (Maeda et al., 2018; McLaughlin et al., 2005). Specifically, we have previously shown that PRLR  
695 does not interact with PI(3,4,5)P<sub>3</sub> (Haxholm et al., 2015). As PI(4,5)P<sub>2</sub> is phosphorylated by the PI3-  
696 kinase to PI(3,4,5)P<sub>3</sub> during PRLR signaling (Aksamitiene et al., 2011; Yamauchi et al., 1998), this  
697 could indicate a way of attenuating signaling. Whether hydrolysis of PI(4,5)P<sub>2</sub> by PLC<sub>γ</sub> is relevant  
698 for PRLR signaling is not known.  
699

## 700 **Conclusions**

701 Signal transduction by single-pass receptors through the membrane is still an enigma. In the present  
702 work we identify co-structure formation of the disordered LID1 of the PRLR, the membrane

703 constituent PI(4,5)P<sub>2</sub> and the FERM-SH2 domain of the JAK2, and demonstrate its importance for  
704 PRLR signalling. This co-structure has at least two orientations, a Y-shaped state extending from the  
705 membrane and a Flat-state with sites hidden in the membrane, the functional roles of which await  
706 further elucidation. The co-structure led to accumulation of PI(4,5)P<sub>2</sub> at the TMD interface and  
707 mutation of residues identified to specifically interact with PI(4,5)P<sub>2</sub> negatively affected PRL-  
708 induced STAT5 activation. Facilitated by the co-structure, the disordered ICJM folds into an extended  
709 structure, tightening the path from the ECD to the ICD. We suggest that the co-structure formed  
710 between receptor, kinase and PI(4,5)P<sub>2</sub> is critical for signal relay from the extracellular to the  
711 intracellular side of the membrane, and that different orientations of the co-structure exist that may  
712 represent inactive and active states.

713

## 714 **Materials and Methods**

### 715 **Expression and purification of TMD<sub>F206-V240</sub>, TMD-ICD<sub>F206-S270</sub> and ICD<sub>G236-Q396</sub>**

716 PRLR-ICD<sub>G236-Q396</sub> was produced as described in (Haxholm et al., 2015), and TMD<sub>F206-V240</sub> and  
717 TMD-ICD<sub>F206-S270</sub> were produced as described in (Bugge et al., 2015).

718

### 719 **Expression and purification of ICD<sub>K235-G313</sub> and variants (K4E, K4G, $\phi$ 4G and GAG)**

720 ICD<sub>K235-G313</sub> and variants hereof, K4E (K251E, K253E, K262E, K264E), K4G (K251G, K253G,  
721 K262G, K264G),  $\phi$ 4G (I252G; F255G, L259G, L260G) and GAG (C242G, I243A, F244G) were all  
722 produced as follows: Competent BL21(DE3) were transformed using heat shock transformation with  
723 pET24a+ plasmids encoding the protein of interest with N-terminal His<sub>6</sub>-SUMO tag. One colony  
724 was used to inoculate 10 mL of LB media with 50  $\mu$ g/mL Kanamycin and incubated overnight at 37  
725 °C at 160 RPM. The overnight culture was used to inoculate 1L M9 minimal media (3 g/l KH<sub>2</sub>PO<sub>4</sub>,  
726 7.5 g/l Na<sub>2</sub>HPO<sub>4</sub>, 5 g/l NaCl, 1 mM MgSO<sub>4</sub>, 4 g/l glucose, 1 g <sup>15</sup>NH<sub>4</sub>Cl<sub>2</sub>, 1ml M2 trace solution, 50  
727  $\mu$ g/mL Kanamycin) and grown at 37 °C. At OD<sub>600</sub> ~0.6 recombinant protein expression was induced  
728 with 0.1 mM IPTG for 4H at 37 °C. Cells were harvested by centrifugation (5000xg, 20 min, 4°C)  
729 and kept at -20 °C until purification. Cells were resuspended in 35 mL Buffer A (10 mM imidazole,  
730 50 mM Tris (pH 8), 150 mM NaCl, 2 mM dithiothreitol (DTT) and lysed with French press at 25  
731 kpsi, followed by centrifugation at 20.000xg, 45 min, 4 °C. The supernatant was applied to 5 mL of  
732 pre-equilibrated Ni-NTA beads and incubated for 15 min followed by 50 mL wash with Buffer B 10  
733 mM Imidazole, 50 mM Tris (pH 8), 1M NaCl, 2mM DTT) and 50 mL wash with Buffer A. Protein  
734 was eluted with 10 mL Buffer C (250 mM Imidazole, 50 mM Tris (pH 8), 150 mM NaCl, 2 mM  
735 DTT). The elution was supplemented with 0.01 mg ULP-1 and dialysed against 1 L of dialysis buffer  
736 (50 mM Tris (pH 8), 150 mM NaCl, 1 mM DTT) overnight at 4 °C. The sample was re-applied to the  
737 Ni-NTA column and incubated for 15 min. Flow through containing cleaved protein was collected,  
738 and the remaining protein was eluted with 10 mL Buffer C. The sample was supplemented with 10  
739 mM DTT before heating at 75 °C for 5 min with gentle rotation of the sample throughout. Sample  
740 was transferred directly to ice for 10-15 min incubation followed by centrifugation at 20.000xg, 10  
741 min, 4 °C. The supernatant was concentrated and supplemented with 5 mM betamercaptoethanol  
742 (b-ME) before application to a HiLoad 16/60 Superdex75 prep grade column equilibrated in 20 mM

743 Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub>, 150 mM NaCl, 5 mM b-ME (pH 7.3). Fractions containing pure protein were  
744 pooled and concentrated

745

### 746 **CD spectroscopy**

747 The peptides covering residues K235-D256 (Pep1) and K253-T280 (Pep2), respectively were  
748 purchased from KJ Ross (DK) at 95% purity from HPLC purification. The peptides were dissolved  
749 in 10 mM Na<sub>2</sub>HPO<sub>4</sub>/Na<sub>2</sub>HPO<sub>4</sub>, pH 7.3 to a final concentration of 40 μM (Pep1) and 25 μM (Pep2)  
750 and titrated with TFE or C<sub>8</sub>-PI(4,5)P<sub>2</sub>. The spectra were recorded in a 1mm Quartz cuvette on a Jasco-  
751 810 spectropolarimeter purged with 8 l/min N<sub>2</sub> at 25 °C. A total of 10 accumulations were acquired  
752 from 260-190 nm with the following settings: 0.5 nm data pitch, 1 nm band width, response time of  
753 2 seconds, scanning speed of 10 nm/min. A background reference was recorded at identical settings  
754 for each sample and subtracted from the relevant spectrum. The spectra were processed by fast  
755 Fourier transform filtering and ellipticity converted to mean residual ellipticity ( $[\theta]_{MRW}$ )

756

### 757 **NMR spectroscopy**

758 *TMD*<sub>F206-V240</sub> and *TMD-ICD*<sub>F206-S270</sub>

759 <sup>15</sup>N-labelled or <sup>13</sup>C,<sup>15</sup>N-labeled *TMD-ICD*<sub>F206-S270</sub> was solubilized in molar excess 1,2-dihexanoyl-  
760 sn-glycero-3-phosphocholine (DHPC) dissolved in 50 mM NaCl, 20 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> buffer,  
761 pH 7.2. Subsequently, the DHPC embedded *TMD-ICD*<sub>F206-S270</sub> was subjected to thorough buffer  
762 exchange in a 3 kDa cutoff spinfilter to remove residuals. For reconstitution into POPC SUVs, <sup>15</sup>N-  
763 labeled *TMD-ICD*<sub>F206-S270</sub> was solubilized in 300 μL 5:1 methanol:chloroform and mixed with molar  
764 excess POPC dissolved in chloroform. The constituents were mixed, followed by evaporation of the  
765 organic solvent under a stream of N<sub>2</sub>. When the lipid film appeared dry, it was either left under a  
766 stream of N<sub>2</sub> or placed under vacuum for at least an hour. The resulting proteoliposome film was  
767 rehydrated with 1 mL of 50 mM NaCl, 20 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> buffer, pH 7.2, followed by  
768 extensive dialysis against the buffer in a 3.5 kDa MWCO dialysis tube at 4 °C. Subsequently, the  
769 proteoliposome solution was sonicated in an ultrasonication bath or, if the solution did not clarify,  
770 with an UP400S Ultrasonic Processor, in rounds of 2 s with 30 s rest between runs. Finally, the sample  
771 was concentrated in a 3 kDa cutoff spinfilter.

772 All NMR samples of <sup>15</sup>N-labelled or <sup>13</sup>C,<sup>15</sup>N-labelled *TMD-ICD*<sub>F206-S270</sub> were added 10% (v/v)  
773 D<sub>2</sub>O, 2 mM tris(2-carboxyethyl)phosphine (TCEP), 1 mM sodium trimethylsilylpropanesulfonate  
774 (DSS), 0.05% (v/v) NaN<sub>3</sub>, and 50 mM NaCl, 20 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> buffer (pH 7.2) to a final  
775 volume of 370 μL followed by pH-adjustment to 7.2 (if needed). All spectra were acquired at 37 °C  
776 because the peak intensities of the TMD region decreased at lower temperatures. Free induction  
777 decays were transformed and visualized in NMRPipe (F Delaglio et al., 1995) and analysed using the  
778 CcpNmr Analysis software (Vranken et al., 2005). Proton chemical shifts were referenced internally  
779 to DSS at 0.00 ppm, with heteronuclei referenced by relative gyromagnetic ratios. For assignments  
780 of backbone nuclei, heteronuclear NMR spectra of a sample containing 0.5 mM <sup>13</sup>C,<sup>15</sup>N-labelled  
781 *TMD-ICD*<sub>F206-S270</sub> in 500 times molar excess DHPC were acquired on a Bruker 750-MHz (<sup>1</sup>H)  
782 equipped with a cryoprobe. HNCACB and CBCA(CO)NH spectra were acquired with 32 and 40 of  
783 transients, respectively, and 20% non-uniform sampling (Mayzel et al., 2014), and used for manual  
784 backbone assignments. SCSs were calculated using random coil chemical shifts from (Kjaergaard et

785 al., 2011) (obtained by supplying primary structure, pH and temperature to the webtool  
786 <http://www1.bio.ku.dk/english/research/bms/research/sbinlab/groups/mak/randomcoil/script/>),  
787 which were subtracted from the assigned TMD-ICD<sub>F206-S270</sub> chemical shifts.  
788 The <sup>1</sup>H,<sup>15</sup>N-HSQC spectrum of 0.4 mM <sup>15</sup>N-labelled TMD-ICD<sub>F206-S270</sub> in POPC SUVs (100 times  
789 molar excess of POPC) was acquired on a Varian INOVA 750- MHz (<sup>1</sup>H) spectrometer equipped  
790 with a room temperature probe. The number of transients was 104.

791

792 *ICD<sub>K235-G313</sub>*

793 ICD<sub>K235-G313</sub> and the four variants (K4E, K4G, phi4G and GAG) were dialyzed at 4 °C overnight  
794 against 20 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> (pH 7.3), 150 mM NaCl. The samples of 50 μM protein were  
795 added 1 mM TCEP, 0.25 mM DSS and 10% (v/v) D<sub>2</sub>O and centrifuged at 20.000 xg, 4 °C for 10 min  
796 and transferred to 5mm Shigemi BMS-3 tubes. All NMR experiments were recorded at 5 °C on a  
797 Bruker Avance III 600 MHz (<sup>1</sup>H) spectrometer equipped with cryogenic probe. Free induction decays  
798 were transformed and processed in qMDD (Orekhov and Jaravine, 2011), phased in NMRDraw  
799 (Frank Delaglio et al., 1995) and analysed in CcpNMR analysis software (Vranken et al., 2005).  
800 Proton chemical shifts were referenced to DSS and nitrogen and carbon to their relative gyromagnetic  
801 ratios. <sup>1</sup>H-<sup>15</sup>N-HSQC experiments were acquired using non-uniform sampling (Mayzel et al., 2014)  
802 and recorded on 50 μM <sup>15</sup>N-ICD<sub>K235-G313</sub> (or variants) in the absence and presence of 5x, 10x and 25x  
803 molar excess of C<sub>8</sub>-PI(4,5)P<sub>2</sub> (Avanti Lipids 850185).

804 Transverse <sup>15</sup>N relaxation rates (*R*<sub>2</sub>) of ICD<sub>K235-G313</sub> and the two variants, K4G and φ4G, were  
805 acquired on Bruker Avance III 600 MHz (<sup>1</sup>H) spectrometer with varying relaxation delays of 0 ms,  
806 33.92 ms, 67.84 ms, 135.68 ms, 169.6 ms, 203.52 ms, 271.36 ms and 339,2 ms, measured in triplicates  
807 and peak intensities fitted to single-exponential decays.

808

### 809 **Cell lines and media**

810 AP1-2PH-PLCδ-GFP cells (From J. Snipper; vector from Addgene plasmid #35142) were grown in  
811 Minimum Essential Medium Eagle (EMEM, Gibco) containing 10% Fetal Bovine Serum (Sigma  
812 Aldrich), 1% penicillin/streptomycin (Sigma), and 1% L-glutamine (Sigma). Stable AP1 clones  
813 expressing 2PH-PLCδ-GFP were grown in the same medium, containing 600 μg/mL geneticin  
814 (Merck-Millipore) to maintain expression of 2PH-PLCδ-GFP. Cell lines were maintained at 37 °C  
815 with 95% humidity and 5% CO<sub>2</sub> and were passaged by gentle trypsination for a maximum of 15  
816 passages.

817

### 818 **Immunoblotting**

819 Cells were grown to ~80% confluence in 6-well plates, washed in ice-cold PBS, lysed in boiling lysis  
820 buffer (1% SDS, 10 mM Tris-HCl, pH 7.5, with phosphatase inhibitors), boiled for 1 min, sonicated,  
821 and centrifuged to clear debris. Identical amounts of protein (12 μg/well) diluted in NuPAGE LDS  
822 sample buffer (Novex) with 50% 0.5M DTT were boiled for 5 min, separated on Bio-Rad 10% Tris-  
823 Glycine gels, and transferred to nitrocellulose membranes using the Trans-Blot Turbo Transfer  
824 system (Bio-Rad). Membranes were stained with Ponceau S to confirm equal loading, blocked for 1  
825 h at 37 °C in blocking buffer (TBST, 5% nonfat dry milk), and incubated with the relevant primary  
826 antibodies in blocking buffer overnight at 4°C. After washing in TBST (TBS + 0.1% Tween-20),



827 membranes were incubated with HRP-conjugated secondary antibodies (1:2000, Sigma), washed in  
828 TBST, and visualized using ECL reagent (Bio-Rad). Protein bands were quantified by densitometry  
829 using ImageJ software, and normalized to those of STAT5 and then to WT.

830

### 831 **Immunofluorescence analysis**

832 For immunofluorescence experiments, cells were grown on 12 mm round glass coverslips to ~80%  
833 confluency and fixed in 2% PFA (30 min at RT). Coverslips were washed three times for 3 x 5 min  
834 in PBS, permeabilized for 15 min (0.5% Triton X-100 in TBS), blocked for 30 min (5% BSA in  
835 TBST), and incubated with primary antibody in TBST + 1% BSA at RT for 1.5 h. Coverslips were  
836 again washed in TBST + 1% BSA, and incubated with AlexaFluor488 and AlexaFluor568 conjugated  
837 secondary antibody (1:600 in TBS + 1% BSA) for 1.5 h. Finally, coverslips were incubated with  
838 DAPI (1:1000) for 5 min to stain nuclei, washed in TBST, and mounted in N-propyl-gallate mounting  
839 medium (2% w/v in PBS/glycerol). Cells were visualized using the Olympus IX83 microscope with  
840 a Yokogawa spinning disc confocal unit, using a 60X/1.4 NA oil emersion objective. Image  
841 adjustments were carried out using ImageJ software. Line scans were performed using the  
842 ColorProfiler ImageJ software plugin.

843

### 844 **Primary antibodies**

845 PRLR (Santa Cruz #SC20992), STAT5 (Santa Cruz #SC835), pSTAT5 (Y964) (Cell Signaling  
846 #CS4322), p150 (BD #BD610473),  $\beta$ -actin (Sigma Aldrich #A5441).

847

### 848 **Modelling of simulated proteins**

#### 849 *PRLR TMD-LID1 on a lipid bilayer*

850 To build a model of the hPRLR-TMD-ICD-LID1 region (G204 to H300) we used the MODELLER  
851 interface of Chimera (Pettersen et al., 2004; Webb and Sali, 2016). The structure of hPRLR-TMD  
852 (PDB 2N7I (Bugge et al., 2016a)) was used as template for the transmembrane helix (in this structure  
853 the residue at position 204 (P) was mutated to a G thus, in our model position 204 corresponds to a  
854 glycine) and due to the lack of structural templates for the ICD, it was modelled as a disordered coil.  
855 This all-atom model was used to build coarse-grained simulation systems where the TMD was  
856 embedded in different lipid bilayers composed of POPC in the upper leaflet and either: i) POPC:POPS  
857 (70:30), ii) POPC:POPS:PI(4,5)P<sub>2</sub> (90:5:5) and iii) POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) in the lower  
858 leaflet using the CHARMM-GUI martini\_maker module (Jo et al., 2008; Qi et al., 2015). The  
859 resulting systems were built using the Martini 2.2 forcefield topology and were later adapted to the  
860 Martini 3 (version m3.b3.2) (Souza and Marrink, 2020) topology using the martinize2.py tool. For  
861 these systems, the PI(4,5)P<sub>2</sub> parameters were adapted from their Martini2.2 version by changing the  
862 names of the beads to the Martini3 naming scheme using as example other available lipids. These  
863 Martini3 PI(4,5)P<sub>2</sub> parameters are available in our github repository (see the Data Availability  
864 section). Secondary structure restraints from the Martini forcefield were only applied to the TMD and  
865 no harmonic bond restraints were defined in the building of these systems.

866

867 *All-atom models of JAK2-FERM-SH2 and its complex with PRLR-ICD<sub>LID1</sub>*

868 To build the JAK2-FERM-SH2 + PRLR-ICD<sub>K235-E284</sub> complex the following structures were used:  
869 JAK1-FERM-SH2 + IFNLR1 (PDB 5L04 (Zhang et al., 2016)), TYK2-FERM-SH2 + IFNAR1 (PDB  
870 4PO6 (Wallweber et al., 2014)) and JAK2-FERM-SH2 (PDB 4Z32 (McNally et al., 2016)). A  
871 structural alignment of the three FERM-SH2 domains was performed with STAMP (Russell and  
872 Barton, 1992) using the Multiseq module (Roberts et al., 2006) of VMD (Humphrey et al., 1996).  
873 The model of PRLR-ICD<sub>K235-E284</sub> was generated with the MODELLER interface of Chimera using as  
874 template the aligned receptor-ICD regions present on the structures 5L04 and 4PO6. A total 200  
875 models were generated, and the best in terms of its DOPE score (Shen and Sali, 2006) was selected  
876 for further use. This resulted in a model of PRLR-ICD<sub>K235-E284</sub> bound to JAK2-FERM-SH2. By  
877 combining this model with chain A of PDB 4Z32, a structural model of the JAK2-FERM-SH2 +  
878 PRLR-ICD<sub>K235-E284</sub> complex was obtained. All-atom simulation systems were built for JAK2-FERM-  
879 SH2 and the JAK2-FERM-SH2+PRLR-ICD<sub>K235-E284</sub> complex model. The missing residues on the  
880 loop of F3 of JAK2-FERM-SH2 were completed using CHARMM-GUI pbd-reader module (Jo et  
881 al., 2014, 2008). Hydrogen atoms were automatically added to the protein using the psfgen plugin of  
882 VMD (Humphrey et al., 1996). Aspartate, glutamate, lysine, and arginine residues were charged, and  
883 histidine residues were neutral. Simulation boxes comprised of solvent and 150 mM NaCl were  
884 generated using the CHARMM-GUI solution-builder module (Jo et al., 2008; Lee et al., 2016) using  
885 CHARMM36m (Huang et al., 2017) parameters and topologies for the protein and the TIP3P water  
886 model for the solvent.

887

#### 888 *Coarsened-grained models of JAK2-FERM-SH2 and its complex with PRLR-ICD<sub>LID1</sub>*

889 To build coarse-grained models of JAK2-FERM-SH2 and complex between JAK2-FERM-SH2 and  
890 PRLR-ICD<sub>K235-E284</sub> complex, a conformation from their respective all-atom MD simulations of the  
891 complex was taken after 150 ns (see below). These conformations were used to generate a CG model  
892 using the martinize.py script. The Martini 2.2 forcefield (de Jong et al., 2013) was used and  
893 intramolecular elastic bonds were defined for JAK2-FERM-SH2 in both systems. To keep the  
894 complex formed and to avoid a “collapse” of the disordered PRLR-ICD<sub>LID1</sub>, inter-molecular harmonic  
895 bonds were also defined between JAK-FERM-SH2 and PRLR-ICD<sub>K235-E284</sub> in the complex. In both  
896 cases, a force constant of 400 kJ mol<sup>-1</sup> nm<sup>-2</sup> and lower and upper elastic bond cut-offs of 5 Å and 9 Å,  
897 respectively were used.

898

#### 899 *Coarse-grained models of JAK2-FERM-SH2 and JAK2-FERM-SH2 + PRLR-ICD<sub>LID1</sub> near a lipid* 900 *bilayer*

901 The relaxed CG-model of the JAK2-FERM-SH2 + PRLR-ICD<sub>LID1</sub> complex or JAK2-FERM-SH2  
902 alone (see below) was placed near (~ 7 Å) pre-equilibrated lipid bilayers with two different  
903 compositions: POPC on the upper leaflet and two different compositions on the lower leaflet: i)  
904 POPC:POPS (70:30), and ii) POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10). The systems were solvated with  
905 water beads and 150 mM NaCl. A total of 16 initial orientations of the protein were generated by  
906 rotating the protein around the x or the y axis (with z being the normal of the membrane).

907

## 908 **Molecular dynamics (MD) simulations**

### 909 *Coarse-grained MD simulations*



910 Coarse-grained MD simulations were performed with Gromacs 2016 or 2018 using the Martini 2.2  
911 force field (de Jong et al., 2013) or the open beta version of the Martini 3 (3.b3.2) force field (Souza  
912 and Marrink, 2020). For the PRLR-TMD-ICD<sub>K235-L284</sub> simulations we increased the strength of  
913 interactions between protein and water by 10% to avoid excessive compaction of the disordered  
914 regions, as has been previously done for IDPs and multi-domain proteins (Kassem et al., 2021; Larsen  
915 et al., 2020; Thomassen et al., 2022). Other simulation parameters, common to all the CG simulations  
916 performed, were chosen following the recommendations in (de Jong et al., 2016). Briefly, a time step  
917 of 20 fs was used, the Verlet cut-off scheme was used considering a buffer tolerance of 0.005 kJ/(mol  
918 ps atom). The reaction-field method was used for Coulomb interactions with a cut-off of 11 Å and a  
919 relative permittivity of  $\epsilon_r = 15$ . For van der Waals' interactions, a cut-off of 11 Å was used. The  
920 velocity rescaling thermostat was employed with a reference temperature of  $T = 310$  K, with a  
921 coupling constant of  $\tau_T = 1$  ps. For the equilibrations, the Berendsen barostat was employed ( $p = 1$   
922 bar,  $\tau_p = 3$  ps), whereas the production runs were performed with a Parrinello-Rahman barostat ( $p =$   
923 1 bar,  $\tau_p = 12$  ps). A semi-isotropic pressure coupling was used for all the systems that contained a  
924 lipid bilayer. For all systems, an initial round of equilibration with decreasing constraints applied to  
925 the protein beads and lipid beads was performed following the protocol provided by CHARMM-GUI  
926 Martini maker module. For the PRLR-TMD-ICD<sub>K235-L284</sub> simulations, a total of 11  $\mu$ s of  
927 unconstrained MD were performed of which the first microsecond was considered as equilibration  
928 and the last 10  $\mu$ s as production and used for analysis. For the JAK2-FERM-SH2 and the complex  
929 between JAK2-FERM-SH2 in solution, 1  $\mu$ s of unconstrained simulation was performed. In the case  
930 of JAK2-FERM-SH2 or the complex between JAK2-FERM-SH2 and PRLR-TMD-ICD<sub>K235-L284</sub> near  
931 a lipid bilayer, an unconstrained run of 5  $\mu$ s was performed for each system and the complete  
932 trajectory considered for analysis.

933

#### 934 *All-atom molecular dynamics simulations*

935 All-atom MD simulations were performed using GROMACS 2016 and 2018 (Abraham et al., 2015),  
936 using the CHARMM36m force field (Huang et al., 2017) for proteins and the TIP3P model for water.  
937 The initial system was minimized followed by position restrained simulation in two different phases,  
938 NVT and NPT. A 150 ns run of unconstrained NPT equilibration was then performed. The Berendsen  
939 thermostat was used for the constrained relaxation runs and the Nose-Hoover thermostat for the  
940 production runs. In all cases, the temperature was 310 K. For the NPT simulations, the Berendsen  
941 barostat was used during relaxations and the Parrinello-Rahman barostat used in unconstrained  
942 production runs. In all cases the target pressure was 1 atm. In all the simulations, the Verlet-cutoff  
943 scheme was used with a 2 fs timestep. A cutoff of 12 Å with a switching function starting at 10 Å was  
944 used for non-bonded interactions along with periodic boundary conditions. The Particle Mesh Ewald  
945 method was used to compute long-range electrostatic forces. Hydrogen atoms were constrained using  
946 the LINCS (Hess et al., 1997) algorithm.

947

#### 948 *Trajectory analyses*

949 Analysis of the obtained trajectories was performed using VMD plugins, GROMACS analysis tools  
950 and in-house prepared tcl and python scripts, available on github (see below). For the characterization  
951 of the orientation of the JAK2-FERM-SH2+PRLR-ICD<sub>K235-E284</sub> complex with respect to the lipid

952 bilayer we used the geographical coordinate system with latitude and longitude devised by Herzog et  
953 al. (Herzog et al., 2017). Lipid densities were calculated with the Volmap plugin from VMD  
954 considering only the PO4 beads and a 1Å grid. Density plots are shown as an enrichment score with  
955 values representing the percentage of enrichment or depletion with respect to the average value on  
956 the system as done previously in (Corradi et al., 2018). All molecular renderings were done with  
957 VMD (Humphrey et al., 1996). Protein-protein contact maps were calculated using CONAN  
958 (Mercadante et al., 2018).

959

## 960 **Acknowledgements**

961 The authors thank the SYNERGY, BRAINSTRUC and REPIN consortia for valuable discussion and  
962 Signe A. Sjørup and Katrine Franklin Mark for skilled technical assistance. We are grateful to Dr.  
963 Julie Schnipper for generating the AP1-2PH-PLCδ-GFP cells and to Prof. Vincent Goffin for initial  
964 discussions regarding the importance of the KxK-motifs in PRLR.

965

## 966 **Additional information**

### 967 **Funding**

968 <i>Funder</i>	968 <i>Grant reference number</i>	968 <i>Author</i>
969 Novo Nordisk Foundation	NNF18OC0033926	Birthe B. Kragelund
970 Novo Nordisk Foundation	NNF15OC0016670	Birthe B. Kragelund, Stine F. Pedersen, 971 Lise Arleth
972 Lundbeck Foundation	BRAINSTRUC	Kresten Lindorff-Larsen, Lise Arleth, 973 Birthe B. Kragelund

974 The funders had no role in study design, data collection and interpretation, or the decision to submit  
975 the work for publication

976

### 977 **Author contributions**

978 **Raul Araya-Secchi**, Formal analysis, Validation, Investigation, Visualization, Methodology,  
979 Writing - original draft; **Katrine Bugge**, Formal analysis, Validation, Investigation, Visualization,  
980 Methodology, Writing - review and editing; **Pernille Seiffert**, Investigation, Visualization,  
981 Methodology, Writing - original draft, Writing - review and editing; **Amalie Petry**, Investigation;  
982 **Gitte W. Haxholm**, Investigation, **Kresten Lindorff-Larsen**, Validation, Supervision, Writing -  
983 review and editing, Funding; **Stine F. Pedersen**, Conceptualization, Resources, Formal analysis,  
984 Supervision, Funding acquisition, Writing - review and editing;; **Lise Arleth**, Conceptualization,  
985 Writing - review and editing; Resources, Formal analysis, Supervision, Funding acquisition; **Birthe**  
986 **B. Kragelund**, Conceptualization, Formal analysis, Validation, Resources, Formal analysis,  
987 Visualization, Supervision, Funding acquisition analysis, Writing - original draft, Writing - review  
988 and editing;

989

### 990 **Author ORCIDs**

991 Raul Araya-Secchi <https://orcid.org/0000-0002-4872-3553>

992 Katrine Bugge <https://orcid.org/0000-0002-6286-6243>

993 Pernille Seiffert <https://orcid.org/0000-0003-4213-5336>

994 Amalie Petry  
995 Gitte W. Haxholm  
996 Kresten Lindorff-Larsen <https://orcid.org/0000-0002-4750-6039>  
997 Stine Falsig Pedersen <https://orcid.org/0000-0002-3044-7714>  
998 Lise Arleth <https://orcid.org/0000-0002-4694-4299>  
999 Birthe B. Kragelund <https://orcid.org/0000-0002-7454-1761>

1000

## 1001 **Additional files**

1002

## 1003 **Supplementary files**

1004 MDAR checklist

1005

## 1006 **Data availability**

1007 All data needed to evaluate the conclusions in the paper are present in the paper and/or the  
1008 Supplementary Materials. The MD data and models together with the scripts used in the trajectory  
1009 analysis are available on Github at [https://github.com/Niels-Bohr-Institute-XNS-](https://github.com/Niels-Bohr-Institute-XNS-StructBiophys/PRLRmodel)  
1010 [StructBiophys/PRLRmodel](https://github.com/Niels-Bohr-Institute-XNS-StructBiophys/PRLRmodel). NMR chemical shifts for the PRLR-ICD<sub>G236-Q396</sub> are deposited in the  
1011 BioMagResBank under the accession number 51695.

1012

## 1013 **REFERENCES**

1014

- 1015 Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E. 2015. GROMACS: High  
1016 performance molecular simulations through multi-level parallelism from laptops to  
1017 supercomputers. *SoftwareX* **1–2**:19–25. doi:10.1016/j.softx.2015.06.001
- 1018 Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A. 2011. Prolactin-  
1019 stimulated activation of ERK1 / 2 mitogen-activated protein kinases is controlled by PI3-  
1020 kinase / Rac / PAK signaling pathway in breast cancer cells. *Cell Signal* **23**:1794–1805.  
1021 doi:10.1016/j.cellsig.2011.06.014
- 1022 Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, Ben-Tal N. 2016. ConSurf 2016: an  
1023 improved methodology to estimate and visualize evolutionary conservation in  
1024 macromolecules. *Nucleic Acids Res* **44**:W344-50. doi:10.1093/nar/gkw408
- 1025 Bachelot A, Binart N. 2007. Reproductive role of prolactin. *Reproduction* **133**:361–369.  
1026 doi:10.1530/REP-06-0299
- 1027 Basak S, Saikia N, Kwun D, Choi UB, Ding F, Bowen ME. 2022. Different Forms of Disorder in  
1028 NMDA-Sensitive Glutamate Receptor Cytoplasmic Domains Are Associated with Differences  
1029 in Condensate Formation. *Biomolecules* **13**. doi:10.3390/BIOM13010004
- 1030 Bocharov E V., Lesovoy DM, Bocharova O V., Urban AS, Pavlov K V., Volynsky PE, Efremov  
1031 RG, Arseniev AS. 2018. Structural basis of the signal transduction via transmembrane domain  
1032 of the human growth hormone receptor. *Biochimica et Biophysica Acta (BBA) - General*  
1033 *Subjects* **1862**:1410–1420. doi:10.1016/j.bbagen.2018.03.022
- 1034 Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. 1998. Prolactin (PRL) and its receptor:  
1035 actionm signal transduction pathways and phenotypes observed in PRL receptor knockout  
1036 mice. *Endocr Rev* **19**:225–268.

- 1037 Bompard G, Martin M, Roy C, Vignon F, Freiss G. 2003. Membrane targeting of protein tyrosine  
1038 phosphatase PTPL1 through its FERM domain via binding to phosphatidylinositol 4,5-  
1039 biphosphate. *J Cell Sci* **116**:2519–30. doi:10.1242/jcs.00448
- 1040 Boutin JM, Jolicoeur C, Okamura H, Gagnon J, Edery M, Shiota M, Banville D, Dusanter-Fourt I,  
1041 Djiane J, Kelly PA. 1988. Cloning and expression of the rat prolactin receptor, a member of  
1042 the growth hormone/prolactin receptor gene family. *Cell* **53**:69–77. doi:10.1016/0092-  
1043 8674(88)90488-6
- 1044 Brooks AJ, Dai W, O’Mara ML, Abankwa D, Chhabra Y, Pelekanos R a, Gardon O, Tunny K a,  
1045 Blucher KM, Morton CJ, Parker MW, Sieracki E, Gambin Y, Gomez G a, Alexandrov K,  
1046 Wilson I a, Doxastakis M, Mark AE, Waters MJ. 2014. Mechanism of Activation of Protein  
1047 Kinase JAK2 by the Growth Hormone Receptor. *Science (1979)* **344**:1249783–1249783.  
1048 doi:10.1126/science.1249783
- 1049 Brooks AJ, Dehkhoda F, Kragelund BB. 2016. Cytokine Receptors. *Principles of Endocrinology  
1050 and Hormone Action*. doi:10.1007/978-3-319-27318-1
- 1051 Broutin I, Jomain J-B, Tallet E, van Agthoven J, Raynal B, Hoos S, Kragelund BB, Kelly P a,  
1052 Ducruix A, England P, Goffin V. 2010. Crystal structure of an affinity-matured prolactin  
1053 complexed to its dimerized receptor reveals the topology of hormone binding site 2. *J Biol  
1054 Chem* **285**:8422–33. doi:10.1074/jbc.M109.089128
- 1055 Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks  
1056 TA, Eidne KA, Parker MW, Waters MJ. 2005. Model for growth hormone receptor activation  
1057 based on subunit rotation within a receptor dimer. *Nat Struct Mol Biol* **12**:814–821.  
1058 doi:10.1038/nsmb977
- 1059 Bugge K, Papaleo E, Haxholm GW, Hopper JTS, Robinson C v, Olsen JG, Lindorff-Larsen K,  
1060 Kragelund BB. 2016. A combined computational and structural model of the full-length  
1061 human prolactin receptor. *Nat Commun* **7**:11578. doi:10.1038/ncomms11578
- 1062 Bugge K, Steinocher H, Brooks AJ, Lindor K, Kragelund BB. 2015. Exploiting Hydrophobicity for  
1063 Efficient Production of Transmembrane Helices for Structure Determination by NMR  
1064 Spectroscopy. *Anal Chem* **87**:9126–9131. doi:10.1021/acs.analchem.5b02365
- 1065 Campbell GS, Argetsinger LS, Ihle JN, Kelly PA, Rillema JA, Carter-Su C. 1994. Activation of  
1066 JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants.  
1067 *Proceedings of the National Academy of Sciences* **91**:5232–5236. doi:10.1073/pnas.91.12.5232
- 1068 Carracedo A, Pandolfi PP. 2008. The PTEN–PI3K pathway: of feedbacks and cross-talks.  
1069 *Oncogene* **27**:5527–5541. doi:10.1038/onc.2008.247
- 1070 Chavent M, Karia D, Kalli AC, Domański J, Duncan AL, Hedger G, Stansfeld PJ, Seiradake E,  
1071 Jones EY, Sansom MSP. 2018. Interactions of the EphA2 Kinase Domain with PIPs in  
1072 Membranes: Implications for Receptor Function. *Structure* **26**:1025-1034.e2.  
1073 doi:10.1016/J.STR.2018.05.003
- 1074 Chhabra Y, Seiffert P, Gormal RS, Vullings M, Lee CMM, Wallis TP, Dehkhoda F, Indrakumar S,  
1075 Jacobsen NL, Lindorff-Larsen K, Durisic N, Waters MJ, Meunier FA, Kragelund BB, Brooks  
1076 A. 2022. Tyrosine Kinases Compete for Growth Hormone Receptor Binding and Regulate  
1077 Receptor Mobility and Degradation. *SSRN Electronic Journal*. doi:10.2139/ssrn.4260495
- 1078 Clevenger C v, Rui H. 2022. Breast Cancer and Prolactin – New Mechanisms and Models.  
1079 *Endocrinology* **163**. doi:10.1210/endo/bqac122
- 1080 Corradi V, Mendez-Villuendas E, Ingólfsson HI, Gu R-X, Siuda I, Melo MN, Moussatova A,  
1081 DeGagné LJ, Sejdiu BI, Singh G, Wassenaar TA, Delgado Magner K, Marrink SJ, Tieleman  
1082 DP. 2018. Lipid–Protein Interactions Are Unique Fingerprints for Membrane Proteins. *ACS  
1083 Cent Sci* **4**:709–717. doi:10.1021/acscentsci.8b00143



- 1084 Dadhich R, Kapoor S. 2022. Lipidomic and Membrane Mechanical Signatures in Triple-Negative  
1085 Breast Cancer: Scope for Membrane-Based Theranostics. *Mol Cell Biochem*.  
1086 doi:10.1007/s11010-022-04459-4
- 1087 de Jong DH, Baoukina S, Ingólfsson HI, Marrink SJ. 2016. Martini straight: Boosting performance  
1088 using a shorter cutoff and GPUs. *Comput Phys Commun* **199**:1–7.  
1089 doi:10.1016/j.cpc.2015.09.014
- 1090 de Jong DH, Singh G, Bennett WFD, Arnarez C, Wassenaar TA, Schäfer L V., Periole X, Tieleman  
1091 DP, Marrink SJ. 2013. Improved Parameters for the Martini Coarse-Grained Protein Force  
1092 Field. *J Chem Theory Comput* **9**:687–697. doi:10.1021/ct300646g
- 1093 de Vos AM, Ultsch M, Kossiakoff AA. 1992. Human growth hormone and extracellular domain of  
1094 its receptor: crystal structure of the complex. *Science* **255**:306–12.
- 1095 Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: a multidimensional  
1096 spectral processing system based on UNIX pipes. *J Biomol NMR* **6**:277–93.
- 1097 Delaglio Frank, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: A  
1098 multidimensional spectral processing system based on UNIX pipes. *J Biomol NMR* **6**:277–293.  
1099 doi:10.1007/BF00197809
- 1100 Feng J, Mertz B. 2015. Novel phosphatidylinositol 4,5-bisphosphate binding sites on focal adhesion  
1101 kinase. *PLoS One* **10**:1–12. doi:10.1371/journal.pone.0132833
- 1102 Ferrao RD, Wallweber HJA, Lupardus PJ. 2018. Receptor-mediated dimerization of JAK2 FERM  
1103 domains is required for JAK2 activation. *Elife* **7**:1–21.
- 1104 Gadd SL, Clevenger C v. 2006. Ligand-independent dimerization of the human prolactin receptor  
1105 isoforms: functional implications. *Mol Endocrinol* **20**:2734–2746. doi:10.1210/me.2006-0114
- 1106 Glassman CR, Tsutsumi N, Saxton RA, Lupardus PJ, Jude KM, Christopher Garcia K. 2022.  
1107 Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation.  
1108 *Science* **376**. doi:10.1126/SCIENCE.ABN8933
- 1109 Goñi GM, Epifano C, Boskovic J, Camacho-Artacho M, Zhou J, Bronowska A, Martín MT, Eck  
1110 MJ, Kremer L, Gräter F, Gervasio FL, Perez-Moreno M, Lietha D. 2014. Phosphatidylinositol  
1111 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and  
1112 conformational changes. *Proc Natl Acad Sci U S A* **111**:E3177-86.  
1113 doi:10.1073/pnas.1317022111
- 1114 Goretzki B, Weidemann C, McCray B, Schäfer SL, Jansen J, Tebbe F, Mitrovic S-A, Nöth J,  
1115 Donahue JK, Jeffries CM, Steinchen W, Stengel F, Sumner CJ, Hummer G, Hellmich UA.  
1116 2023. Crosstalk between regulatory elements in the disordered TRPV4 N-terminus modulates  
1117 lipid-dependent channel activity. *bioRxiv*. doi:10.1101/2022.12.21.521430
- 1118 Hamada K, Shimizu T, Matsui T, Tsukita S, Hakoshima T. 2000. Structural basis of the membrane-  
1119 targeting and unmasking mechanisms of the radixin FERM domain. *EMBO J* **19**:4449–62.  
1120 doi:10.1093/emboj/19.17.4449
- 1121 Hannan FM, Elajnaf T, Vandenberg LN, Kennedy SH, Thakker R v. 2022. Hormonal regulation of  
1122 mammary gland development and lactation. *Nat Rev Endocrinol*. doi:10.1038/s41574-022-  
1123 00742-y
- 1124 Haxholm GW, Nikolajsen LF, Olsen JG, Fredsted J, Larsen FH, Goffin V, Pedersen SF, Brooks AJ,  
1125 Waters MJ, Kragelund BB. 2015. Intrinsically disordered cytoplasmic domains of two  
1126 cytokine receptors mediate conserved interactions with membranes. *Biochem J* **468**:495–506.  
1127 doi:10.1042/BJ20141243
- 1128 Hedger G, Sansom MSP, Koldsø H. 2015a. The juxtamembrane regions of human receptor tyrosine  
1129 kinases exhibit conserved interaction sites with anionic lipids. *Sci Rep* **5**:9198.  
1130 doi:10.1038/srep09198

- 1131 Hedger G, Sansom MSP, Koldsø H. 2015b. The juxtamembrane regions of human receptor tyrosine  
1132 kinases exhibit conserved interaction sites with anionic lipids. *Sci Rep* **5**:9198.  
1133 doi:10.1038/srep09198
- 1134 Herzog FA, Braun L, Schoen I, Vogel V. 2017. Structural Insights How PIP2 Imposes Preferred  
1135 Binding Orientations of FAK at Lipid Membranes. *J Phys Chem B* **121**:3523–3535.  
1136 doi:10.1021/acs.jpcc.6b09349
- 1137 Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. 1997. LINCS: A linear constraint solver for  
1138 molecular simulations. *J Comput Chem* **18**:1463–1472. doi:10.1002/(SICI)1096-  
1139 987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
- 1140 Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, Grubmüller H, MacKerell AD.  
1141 2017. CHARMM36m: an improved force field for folded and intrinsically disordered proteins.  
1142 *Nat Methods* **14**:71–73. doi:10.1038/nmeth.4067
- 1143 Huang LJ shen, Constantinescu SN, Lodish HF. 2001. The N-terminal domain of Janus kinase 2 is  
1144 required for Golgi processing and cell surface expression of erythropoietin receptor. *Mol Cell*  
1145 **8**:1327–1338. doi:10.1016/S1097-2765(01)00401-4
- 1146 Humphrey W, Dalke A, Schulten K. 1996. VMD: Visual molecular dynamics. *J Mol Graph* **14**:33–  
1147 38. doi:10.1016/0263-7855(96)00018-5
- 1148 Jo S, Cheng X, Islam SM, Huang L, Rui H, Zhu A, Lee HS, Qi Y, Han W, Vanommeslaeghe K,  
1149 MacKerell AD, Roux B, Im W. 2014. CHARMM-GUI PDB Manipulator for Advanced  
1150 Modeling and Simulations of Proteins Containing Nonstandard Residues. pp. 235–265.  
1151 doi:10.1016/bs.apcsb.2014.06.002
- 1152 Jo S, Kim T, Iyer VG, Im W. 2008. CHARMM-GUI: A web-based graphical user interface for  
1153 CHARMM. *J Comput Chem* **29**:1859–1865. doi:10.1002/jcc.20945
- 1154 Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R,  
1155 Židek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-  
1156 Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M,  
1157 Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW,  
1158 Kavukcuoglu K, Kohli P, Hassabis D. 2021. Highly accurate protein structure prediction with  
1159 AlphaFold. *Nature* **596**:583–589. doi:10.1038/s41586-021-03819-2
- 1160 Kassem N, Araya-Secchi R, Bugge K, Barclay A, Steinocher H, Khondker A, Wang Y, Lenard AJ,  
1161 Bürck J, Sahin C, Ulrich AS, Landreh M, Pedersen MC, Rheinstädter MC, Pedersen PA,  
1162 Lindorff-Larsen K, Arleth L, Kragelund BB. 2021. Order and disorder—An integrative  
1163 structure of the full-length human growth hormone receptor. *Sci Adv* **7**:eabh3805.  
1164 doi:10.1126/sciadv.abh3805
- 1165 Khan HM, Souza PCT, Thallmair S, Barnoud J, De Vries AH, Marrink SJ, Reuter N. 2020.  
1166 Capturing Choline-Aromatics Cation- $\pi$  Interactions in the MARTINI Force Field. *J Chem*  
1167 *Theory Comput* **16**:2550–2560. doi:10.1021/ACS.JCTC.9B01194
- 1168 Kjaergaard M, Brander S, Poulsen FM. 2011. Random coil chemical shift for intrinsically  
1169 disordered proteins: Effects of temperature and pH. *J Biomol NMR* **49**:139–149.  
1170 doi:10.1007/s10858-011-9472-x
- 1171 Kjaergaard M, Kragelund BB. 2017. Functions of intrinsic disorder in transmembrane proteins.  
1172 *Cellular and Molecular Life Sciences* **74**:3205–3224. doi:10.1007/s00018-017-2562-5
- 1173 Kubatzky KF, Ruan W, Gurezka R, Cohen J, Ketteler R, Watowich SS, Neumann D, Langosch D,  
1174 Klingmüller U. 2001. Self assembly of the transmembrane domain promotes signal  
1175 transduction through the erythropoietin receptor. *Current Biology* **11**:110–115.  
1176 doi:10.1016/S0960-9822(01)00018-5



- 1177 Landau M, Mayrose I, Rosenberg Y, Glaser F, Martz E, Pupko T, Ben-Tal N. 2005. ConSurf 2005:  
1178 the projection of evolutionary conservation scores of residues on protein structures. *Nucleic*  
1179 *Acids Res* **33**:W299-302. doi:10.1093/nar/gki370
- 1180 Larsen AH, John LH, Sansom MSP, Corey RA. 2022. Specific interactions of peripheral membrane  
1181 proteins with lipids: what can molecular simulations show us? *Biosci Rep* **42**.  
1182 doi:10.1042/BSR20211406
- 1183 Larsen AH, Wang Y, Bottaro S, Grudinin S, Arleth L, Lindorff-Larsen K. 2020. Combining  
1184 molecular dynamics simulations with small-angle X-ray and neutron scattering data to study  
1185 multi-domain proteins in solution. *PLoS Comput Biol* **16**:e1007870.  
1186 doi:10.1371/journal.pcbi.1007870
- 1187 Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, Wei S, Buckner J, Jeong JC, Qi  
1188 Y, Jo S, Pande VS, Case DA, Brooks CL, MacKerell AD, Klauda JB, Im W. 2016.  
1189 CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and  
1190 CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. *J Chem*  
1191 *Theory Comput* **12**:405–413. doi:10.1021/acs.jctc.5b00935
- 1192 Lu J, Dong W, Hammond GR, Hong Y. 2022. Hypoxia controls plasma membrane targeting of  
1193 polarity proteins by dynamic turnover of PI4P and PI(4,5)P2. *Elife* **11**.  
1194 doi:10.7554/eLife.79582
- 1195 Maeda R, Sato T, Okamoto K, Yanagawa M, Sako Y. 2018. Lipid-Protein Interplay in Dimerization  
1196 of Juxtamembrane Domains of Epidermal Growth Factor Receptor. *Biophys J* **114**:893–903.  
1197 doi:10.1016/j.bpj.2017.12.029
- 1198 Mani T, Hennigan RF, Foster LA, Conrady DG, Herr AB, Ip W. 2011. FERM Domain  
1199 Phosphoinositide Binding Targets Merlin to the Membrane and Is Essential for Its Growth-  
1200 Suppressive Function. *Mol Cell Biol* **31**:1983–1996. doi:10.1128/MCB.00609-10
- 1201 Mayzel M, Rosenlo J, Orekhov VY. 2014. Time-resolved multidimensional NMR with non-  
1202 uniform sampling. *J Biomol NMR* **58**:129–139. doi:10.1007/s10858-013-9811-1
- 1203 McLaughlin S, Smith SO, Hayman MJ, Murray D. 2005. An Electrostatic Engine Model for  
1204 Autoinhibition and Activation of the Epidermal Growth Factor Receptor (EGFR/ErbB)  
1205 Family. *Journal of General Physiology* **126**:41–53. doi:10.1085/jgp.200509274
- 1206 McLaughlin S, Wang J, Gambhir A, Murray D. 2002. PIP(2) and proteins: interactions,  
1207 organization, and information flow. *Annu Rev Biophys Biomol Struct* **31**:151–75.  
1208 doi:10.1146/annurev.biophys.31.082901.134259
- 1209 McNally R, Toms A V., Eck MJ. 2016. Crystal Structure of the FERM-SH2 Module of Human  
1210 Jak2. *PLoS One* **11**:e0156218. doi:10.1371/journal.pone.0156218
- 1211 Mercadante D, Gräter F, Daday C. 2018. CONAN: A Tool to Decode Dynamical Information from  
1212 Molecular Interaction Maps. *Biophys J* **114**:1267–1273. doi:10.1016/j.bpj.2018.01.033
- 1213 Metcalf DG, Moore DT, Wu Y, Kielec JM, Molnar K, Valentine KG, Wand AJ, Bennett JS,  
1214 DeGrado WF. 2010. NMR analysis of the  $\alpha$ IIb $\beta$ 3 cytoplasmic interaction suggests a  
1215 mechanism for integrin regulation. *Proceedings of the National Academy of Sciences*  
1216 **107**:22481–22486. doi:10.1073/pnas.1015545107
- 1217 Morris R, Kershaw NJ, Babon JJ. 2018. The molecular details of cytokine signaling via the  
1218 JAK/STAT pathway. *Protein Science* **27**:1984–2009. doi:10.1002/pro.3519
- 1219 Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van  
1220 der Merwe PA, Klenerman P, Bountra C, Thakker R v. 2013. Mutant Prolactin Receptor and  
1221 Familial Hyperprolactinemia. *New England Journal of Medicine* **369**:2012–2020.  
1222 doi:10.1056/NEJMoa1307557

- 1223 Orekhov VY, Jaravine VA. 2011. Analysis of non-uniformly sampled spectra with multi-  
1224 dimensional decomposition. *Prog Nucl Magn Reson Spectrosc* **59**:271–292.  
1225 doi:10.1016/j.pnmrs.2011.02.002
- 1226 Park MJ, Sheng R, Silkov A, Jung DJ, Wang ZG, Xin Y, Kim H, Thiagarajan-Rosenkranz P, Song  
1227 S, Yoon Y, Nam W, Kim I, Kim E, Lee DG, Chen Y, Singaram I, Wang L, Jang MH, Hwang  
1228 CS, Honig B, Ryu S, Lorieau J, Kim YM, Cho W. 2016. SH2 Domains Serve as Lipid-Binding  
1229 Modules for pTyr-Signaling Proteins. *Mol Cell* **62**. doi:10.1016/j.molcel.2016.01.027
- 1230 Patwardhan P, Resh MD. 2010. Myristoylation and membrane binding regulate c-Src stability and  
1231 kinase activity. *Mol Cell Biol* **30**:4094–4107. doi:10.1128/MCB.00246-10
- 1232 Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004.  
1233 UCSF Chimera - A visualization system for exploratory research and analysis. *J Comput Chem*  
1234 **25**:1605–1612. doi:10.1002/jcc.20084
- 1235 Pezet A, Buteau H, Kelly PA, Edery M. 1997. The last proline of Box 1 is essential for association  
1236 with JAK2 and functional activation of the prolactin receptor. *Mol Cell Endocrinol* **129**:199–  
1237 208. doi:10.1016/S0303-7207(97)00063-4
- 1238 Qi Y, Ingólfsson HI, Cheng X, Lee J, Marrink SJ, Im W. 2015. CHARMM-GUI Martini Maker for  
1239 Coarse-Grained Simulations with the Martini Force Field. *J Chem Theory Comput* **11**:4486–  
1240 4494. doi:10.1021/acs.jctc.5b00513
- 1241 Rawat A, Harishchandran A, Nagaraj R. 2013. Fatty acyl chain-dependent but charge-independent  
1242 association of the SH4 domain of Lck with lipid membranes. *J Biosci* **38**:63–71.  
1243 doi:10.1007/s12038-012-9288-1
- 1244 Rawat A, Nagaraj R. 2010. Determinants of membrane association in the SH4 domain of Fyn: roles  
1245 of N-terminus myristoylation and side-chain thioacylation. *Biochim Biophys Acta* **1798**:1854–  
1246 63. doi:10.1016/j.bbamem.2010.06.009
- 1247 Roberts E, Eargle J, Wright D, Luthey-Schulten Z. 2006. MultiSeq: unifying sequence and structure  
1248 data for evolutionary analysis. *BMC Bioinformatics* **7**:382. doi:10.1186/1471-2105-7-382
- 1249 Rowlinson SW, Yoshizato H, Barclay JL, Brooks AJ, Behncken SN, Kerr LM, Millard K,  
1250 Palethorpe K, Nielsen K, Clyde-Smith J, Hancock JF, Waters MJ. 2008. An agonist-induced  
1251 conformational change in the growth hormone receptor determines the choice of signalling  
1252 pathway. *Nat Cell Biol* **10**:740–7. doi:10.1038/ncb1737
- 1253 Rui H, Kirken RA, Farrar WL. 1994. Activation of receptor-associated tyrosine kinase JAK2 by  
1254 prolactin. *J Biol Chem* **269**:5364–8.
- 1255 Russell RB, Barton GJ. 1992. Multiple protein sequence alignment from tertiary structure  
1256 comparison: Assignment of global and residue confidence levels. *Proteins: Structure,  
1257 Function, and Genetics* **14**:309–323. doi:10.1002/prot.340140216
- 1258 Sackmann-Sala L, Goffin V. 2015. Prolactin-Induced Prostate Tumorigenesis. pp. 221–242.  
1259 doi:10.1007/978-3-319-12114-7\_10
- 1260 Seiffert P, Bugge K, Nygaard M, Haxholm GW, Martinsen JH, Pedersen MN, Arleth L, Boomsma  
1261 W, Kragelund BB. 2020a. Orchestration of signaling by structural disorder in class 1 cytokine  
1262 receptors. *Cell Communication and Signaling* **18**. doi:10.1186/s12964-020-00626-6
- 1263 Seiffert P, Bugge K, Nygaard M, Haxholm GW, Martinsen JH, Pedersen MN, Arleth L, Boomsma  
1264 W, Kragelund BB. 2020b. Orchestration of signaling by structural disorder in class 1 cytokine  
1265 receptors. *Cell Communication and Signaling* **18**. doi:10.1186/s12964-020-00626-6
- 1266 Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, Smith SO,  
1267 Constantinescu SN. 2003. Active and Inactive Orientations of the Transmembrane and  
1268 Cytosolic Domains of the Erythropoietin Receptor Dimer. *Mol Cell* **12**:1239–1250.
- 1269 Shen M-Y, Sali A. 2006. Statistical potential for assessment and prediction of protein structures.  
1270 *Protein Sci* **15**:2507–24. doi:10.1110/ps.062416606

- 1271 Sheng R, Jung DJ, Silkov A, Kim H, Singaram I, Wang ZG, Xin Y, Kim E, Park MJ, Thiagarajan-  
1272 Rosenkranz P, Smrt S, Honig B, Baek K, Ryu S, Lorieau J, Kim YM, Cho W. 2016. Lipids  
1273 regulate Lck protein activity through their interactions with the Lck Src homology 2 domain.  
1274 *Journal of Biological Chemistry* **291**:17639–17650. doi:10.1074/jbc.M116.720284  
1275 Souza PCT, Marrink SJS. 2020. Martini 3 - Open Beta-Release. <http://cgmartini.nl>.  
1276 Stefanski KM, Russell CM, Westerfield JM, Lamichhane R, Barrera FN. 2021. PIP2promotes  
1277 conformation-specific dimerization of the EphA2 membrane region. *Journal of Biological*  
1278 *Chemistry* **296**. doi:10.1074/jbc.RA120.016423  
1279 Suh BC, Hille B. 2005. Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. *Curr*  
1280 *Opin Neurobiol* **15**:370–378. doi:10.1016/J.CONB.2005.05.005  
1281 Thomassen FE, Pesce F, Roesgaard MA, Tesei G, Lindorff-Larsen K. 2022. Improving Martini 3 for  
1282 Disordered and Multidomain Proteins. *J Chem Theory Comput* **18**:2033–2041.  
1283 doi:10.1021/acs.jctc.1c01042  
1284 Trimble WS, Grinstein S. 2015. Barriers to the free diffusion of proteins and lipids in the plasma  
1285 membrane. *Journal of Cell Biology* **208**:259–271. doi:10.1083/jcb.201410071  
1286 van den Bogaart G, Meyenberg K, Risselada HJ, Amin H, Willig KI, Hubrich BE, Dier M, Hell  
1287 SW, Grubmüller H, Diederichsen U, Jahn R. 2011. Membrane protein sequestering by ionic  
1288 protein–lipid interactions. *Nature* **479**:552–555. doi:10.1038/nature10545  
1289 Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G,  
1290 Laydon A, Židek A, Green T, Tunyasuvunakool K, Petersen S, Jumper J, Clancy E, Green R,  
1291 Vora A, Lutfi M, Figurnov M, Cowie A, Hobbs N, Kohli P, Kleywegt G, Birney E, Hassabis  
1292 D, Velankar S. 2022. AlphaFold Protein Structure Database: massively expanding the  
1293 structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res*  
1294 **50**:D439–D444. doi:10.1093/nar/gkab1061  
1295 Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, Llinas M, Ulrich EL, Markley JL,  
1296 Ionides J, Laue ED. 2005. The CCPN data model for NMR spectroscopy: Development of a  
1297 software pipeline. *Proteins: Structure, Function, and Bioinformatics* **59**:687–696.  
1298 doi:10.1002/prot.20449  
1299 Wallweber HJA, Tam C, Franke Y, Starovasnik MA, Lupardus PJ. 2014. Structural basis of  
1300 recognition of interferon- $\alpha$  receptor by tyrosine kinase 2. *Nat Struct Mol Biol* **21**:443–448.  
1301 doi:10.1038/nsmb.2807  
1302 Webb B, Sali A. 2016. Comparative Protein Structure Modeling Using MODELLER. *Curr Protoc*  
1303 *Bioinformatics* **54**. doi:10.1002/cpbi.3  
1304 Wilmes S, Hafer M, Vuorio J, Tucker JA, Winkelmann H, Löchte S, Stanly TA, Pulgar Prieto KD,  
1305 Poojari C, Sharma V, Richter CP, Kurre R, Hubbard SR, Garcia KC, Moraga I, Vattulainen I,  
1306 Hitchcock IS, Piehler J. 2020. Mechanism of homodimeric cytokine receptor activation and  
1307 dysregulation by oncogenic mutations. *Science (1979)* **367**:643–652.  
1308 doi:10.1126/science.aaw3242  
1309 Yamauchi T, Kaburagi Y, Ueki K, Tsuji Y, Stark GR, Kerr IM, Tsushima T, Akanuma Y, Komuro  
1310 I, Tobe K, Yazaki Y, Kadowaki T. 1998. Growth Hormone and Prolactin Stimulate Tyrosine  
1311 Phosphorylation of Insulin Receptor Substrate-1, -2, and -3, Their Association with p85  
1312 Phosphatidylinositol 3-Kinase (PI3-kinase), and Concomitantly PI3-kinase Activation via  
1313 JAK2 Kinase. *Journal of Biological Chemistry* **273**:15719–15726.  
1314 doi:10.1074/jbc.273.25.15719  
1315 Zhang D, Wlodawer A, Lubkowski J. 2016. Crystal Structure of a Complex of the Intracellular  
1316 Domain of Interferon  $\lambda$  Receptor 1 (IFNLR1) and the FERM/SH2 Domains of Human JAK1. *J*  
1317 *Mol Biol* **428**:4651–4668. doi:10.1016/j.jmb.2016.10.005  
1318

1319

## 1320 FIGURE LEGENDS

1321 **Fig. 1: Schematics of the PRLR:PRL:JAK2 complex in the membrane.** The PRLR is shown in  
1322 light blue, the PRL as a dark blue triangle, the PRLR-ICD as a disordered chain and JAK2 in purple.  
1323 The PI(4,5)P<sub>2</sub> lipid (PIP<sub>2</sub>) is shown in orange. The intracellular juxtamembrane (ICJM) region and  
1324 BOX1 of PRLR-ICD are highlighted in green nuances, while the three LIDs as defined in Haxholm  
1325 et al., (Haxholm et al., 2015) are highlighted in red. For simplicity only one of the two ICDs is shown  
1326 associated with JAK2 via the BOX1 (green) and BOX2 (orange) motifs.

1327

1328 **Fig. 2: The ICJM region of the PRLR interacts with PI(4,5)P<sub>2</sub>.** **A)** Overview of investigated PRLR  
1329 variants. **B)** Secondary chemical shifts (SCSs) of TMD-ICD<sub>F206-S270</sub> reconstituted in DHPC micelles.  
1330 **C)** Correlation plot of the SCSs of ICD<sub>G236-Q396</sub> plotted against those of TMD-ICD<sub>F206-S270</sub>. **D)** <sup>15</sup>N, <sup>1</sup>H-  
1331 HSQC spectra of <sup>15</sup>N-ICD<sub>K235-G313</sub> titrated with 5x, 10x and 25x molar excess of C<sub>8</sub>-PI(4,5)P<sub>2</sub>. **E)**  
1332 Structure of C<sub>8</sub>-PI(4,5)P<sub>2</sub>. **F)** Backbone amide chemical shift perturbations (CSPs) and peak intensity  
1333 changes upon addition of C<sub>8</sub>-PI(4,5)P<sub>2</sub> to <sup>15</sup>N-ICD<sub>K235-G313</sub> plotted against residue number. **G) Top:**  
1334 Far-UV CD spectra of Pep1 titrated with C<sub>8</sub>-PI(4,5)P<sub>2</sub> or in 65% TFE. **Middle:** Far-UV CD spectra  
1335 of Pep1 in the presence of 5x-38x C<sub>8</sub>-PI(4,5)P<sub>2</sub> subtracted with the spectrum of Pep1 in the absence  
1336 of C<sub>8</sub>-PI(4,5)P<sub>2</sub>. **Bottom:** Far-UV CD spectra of Pep2 titrated with C<sub>8</sub>-PI(4,5)P<sub>2</sub> or in 65% TFE.

1337 **Figure supplement 1:** <sup>15</sup>N, <sup>1</sup>H-HSQC spectra of *A)* TMD<sub>F206-V240</sub> and TMD-ICD<sub>F206-S270</sub> in DHPC  
1338 micelles, and *B)* TMD-ICD<sub>F206-S270</sub> in POPC SUVs.

1339 **Figure supplement 2:** C<sup>α</sup> secondary chemical shifts of ICD<sub>G236-Q396</sub>

1340

1341 **Fig. 3. Protein – lipid interactions of PRLR-ICD<sub>LID1</sub> obtained from CG-MD simulations.** **(A-**  
1342 **B)** Protein – lipids contact histograms for PRLR-ICD<sub>LID1</sub>+POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10). **A)**  
1343 Contacts between the protein and lipid headgroups. A contact is counted if the distance between the  
1344 backbone beads of the protein is ≤ 7 Å from the head-group beads of the lipids. **B)** Contacts between  
1345 the protein and the acyl chains of the lipids. A contact is counted if the distance between the backbone  
1346 bead of the protein is ≤ 7 Å from the acyl-chain bead of the lipids. **C)** Correlation between the change  
1347 in NMR signal and the contact frequency between PRLR-ICD<sub>LID1</sub> and the lipid headgroups from the  
1348 PRLR-ICD<sub>LID1</sub> + POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) system. Pearson correlation coefficient of -0.55  
1349 with  $p = 4.0 \times 10^{-5}$  and  $R^2 = 0.3$ . **D)** Average PI(4,5)P<sub>2</sub> density map (*xy*-plane) taken from the PRLR-  
1350 ICD<sub>LID1</sub> + POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) simulation. The map is colored according to the  
1351 enrichment/depletion percentage with respect to the average density value. **E)** Schematic  
1352 representation of how the interactions and the embedment into the membrane of PRLR contribute to  
1353 the co-structure formation. The data from the simulations correspond to those of the production stage  
1354 (see methods).

1355

1356 **Figure supplement 1:** Protein – lipid interactions of PRLR-ICD<sub>LID1</sub> obtained from CG-MD  
1357 simulations using the martini 3.0b3.2 forcefield

1358 **Figure supplement 2:** Complementary analysis of the Protein e Protein – lipid interactions of PRLR-  
1359 ICD<sub>LID1</sub> obtained from CG-MD simulations.

1360



1361 **Fig. 4. Protein – lipid interactions of the JAK2-FERM-SH2 PRLR-ICD<sub>LID1</sub> complex obtained**  
1362 **from CG-MD simulations. A)** Schematic representation of the simulated system. Combined **B)**  
1363 JAK2-FERM-SH2-lipid and **C)** PRLR-ICD<sub>LID1</sub>-lipid contact frequency histograms for the 16 CG  
1364 simulations of the JAK2-FERM-SH2 +PRLR-ICD<sub>LID1</sub>+ POPC:POPS:PI(4,5)P<sub>2</sub> system. **D)**  
1365 Distribution of the orientations adopted by the JAK2-FERM-SH2 + PRLR-ICD<sub>LID1</sub> complex when  
1366 bound to lipids taken from the 16 simulations with POPC:POPS:PI(4,5)P<sub>2</sub> in the lower-leaflet. The  
1367 snapshots surrounding the map correspond to representative conformations of the highlighted states  
1368 also indicating the fraction total bound time for which each state was observed. Representative  
1369 conformations of **E)** State 2 and **F)** State 4. The grey cylinder depicts the position where PRLR-TMD  
1370 should be located. Representative protein-lipid contact histograms for **G)** State2 and **H)** State4  
1371 colored as in panels B and C.

1372 **Figure supplement 1:** *Analysis of the JAK2-FERM-SH2- PRLR-ICD<sub>LID1</sub> AA-MD simulation.*

1373 **Figure supplement 2.** *Complementary analysis of Protein – lipid interactions of the JAK2-FERM-*  
1374 *SH2 PRLR-ICD<sub>LID1</sub> complex obtained from CG-MD simulations*

1375 **Figure supplement 3.** *Snapshots of the different binding states observed for the JAK2-FERM-SH2 –*  
1376 *PRLR-ICD<sub>LID1</sub> complex with the complete structural model of JAK2*

1377

1378 **Fig. 5. PRLR variants with mutations in lipid interacting residues exhibit decreased PRL-**  
1379 **stimulated STAT5 activation in AP1-2PH-PLC $\delta$ -GFP cells. A)** NMR intensity changes of  
1380 ICD<sub>K235-G313</sub> WT, K4G, K4E,  $\phi$ 4G and GAG variants upon titration with 5x, 10x and 25x molar  
1381 excess C<sub>8</sub>-PI(4,5)P<sub>2</sub> plotted against residue number. **B)** The PRLR variants (WT, K4G, K4E,  $\phi$ 4G,  
1382 3GAG) were transiently transfected in AP1 cells stably expressing the 2PH-PLC $\delta$ -GFP construct  
1383 which visualizes the plasma membrane by binding PI(4,5)P<sub>2</sub>. The cells were subsequently analysed  
1384 by immunofluorescence microscopy, using antibodies against PRLR (magenta) and GFP (green), as  
1385 well as DAPI (blue) to mark nuclei. To the right, examples of an average line-scan for each PRLR  
1386 variant is shown. The fluorescence intensity depicted along the white line drawn (arrow) and green  
1387 fluorescence (plasma membrane) was used to divide the line in a plasma membrane section and  
1388 intracellular section, and relative membrane localization was calculated as the average fluorescence  
1389 of PRLR in the membrane section divided by that in the intracellular section. **C, D)** AP1-2PH-PLC $\delta$ -  
1390 GFP cells were transiently transfected with PRLR variants (WT, K4G, K4E,  $\phi$ 4G, 3GAG, K2E<sub>253</sub>,  
1391 K2E<sub>261</sub>) and incubated overnight followed by serum starvation for 16-17 h and were subsequently  
1392 incubated with or without 10 nM prolactin for 30 min. The resulting lysates were analysed by western  
1393 blot for STAT5, pSTAT5 (Y964), PRLR,  $\beta$ -actin and p150 levels. The immunoblots are  
1394 representative of three biological replicates. **E)** Ratio of plasma membrane localized receptor  
1395 compared to intracellular receptor, analysed by line-scans as in B. Each point represents an individual  
1396 cell, and data are based on three independent biological experiments per condition. Graphs show  
1397 means with SEM error bars. \*P<0.05, \*\*P<0.01 and \*\*\*\*P<0.0001. One-way ANOVA compared to  
1398 WT, unpaired. **F)** Quantification of western blot results shown as pSTAT5 normalized to total  
1399 STAT5, relative to the WT condition. Graphs show means with SEM error bars. \*P<0.05 and  
1400 \*\*P<0.01. One-way ANOVA compared to WT, unpaired.

1401 **Source file 1:** Raw western blots (relating to *figure 5C*)

1402 **Source file 2:** Raw western blot (relating to *figure 5D*)



1403 **Source file 3:** Data summaries (relating to *figure 5E,F*)

1404 **Figure supplement 1:** *Chemical shift perturbations of ICD<sub>K235-G313</sub> of A) WT, B) K4E, C) GAG, D)*  
1405 *K4G and E)  $\phi$ 4G variants.*

1406 **Figure supplement 2:** *<sup>15</sup>N R<sub>2</sub> relaxation rates of ICD<sub>K235-G313</sub> of WT (grey bars), K4G (blue dots)*  
1407 *and  $\phi$ 4G (red squares) variants.*

1408

1409 **Fig. 6. Model of how co-structure formation between JAK2, PRLR and PI4(4,5)P<sub>2</sub> may**  
1410 **contribute to signalling fidelity.** The suggested states in signalling would be **A)** the inactive state of  
1411 the co-structure exemplified by the Flat orientation. **B)** The hormone bound state exemplified by the  
1412 co-structure in the Y orientation. **C)** Phosphorylation of PIP(4,5)P<sub>2</sub> to PI(3,4,5)P<sub>3</sub> for which the PRLR  
1413 has no affinity may lead to downregulation and/or termination of signalling. The colour scheme of  
1414 the proteins is identical to Fig.4.

1415

1416 **Figure supplements and Supplementary files**

1417

1418 **The prolactin receptor scaffolds Janus kinase 2 via co-structure**  
1419 **formation with phosphoinositide-4,5-bisphosphate**

1420 Raul Araya-Secchi<sup>1,2</sup>, Katrine Bugge<sup>3#</sup>, Pernille Seiffert<sup>3#</sup>, Amalie Petry<sup>4</sup>, Gitte W. Haxholm<sup>3</sup>,  
1421 Kresten Lindorff-Larsen<sup>3</sup>, Stine F. Pedersen<sup>4\*</sup>, Lise Arleth<sup>1\*</sup> and Birthe B. Kragelund<sup>3\*</sup>

1422

1423 <sup>1</sup>Structural Biophysics, Section for Neutron and X-ray Science, Niels Bohr Institute, University of  
1424 Copenhagen, 2100 Copenhagen, Denmark.

1425 <sup>2</sup>Facultad de Ingenieria Arquitectura y Diseño, Universidad San Sebastian, Bellavista 7, Santiago,  
1426 Chile.

1427 <sup>3</sup>Structural Biology and NMR Laboratory (SBiNLab), Department of Biology, University of  
1428 Copenhagen, 2200 Copenhagen, Denmark.

1429 <sup>4</sup>Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, 2200  
1430 Copenhagen N, Denmark

1431

1432

1433 **Overview of contents:**

1434 **Figure supplements for main figures:**

1435 **Figure 2 – Figure supplement 1:** <sup>15</sup>N, <sup>1</sup>H-HSQC of TMD<sub>F206-V240</sub>, TMD-ICD<sub>F206-S270</sub> in DHPC micelles (A)  
1436 and TMD-ICD<sub>F206-S270</sub> in POPC SUVs (B)

1437 **Figure 2 – Figure supplement 2:** C $\alpha$  secondary chemical shifts of ICD<sub>G236-Q396</sub>

1438 **Figure 3 - Figure supplement 1:** Protein – lipid interactions of PRLR-ICD<sub>LID1</sub> obtained from CG-MD  
1439 simulations using the martini 3.0b3.2 forcefield

1440 **Figure 3 - Figure supplement 2:** Complementary analysis of the Protein – lipid interactions of PRLR-ICD<sub>LID1</sub>  
1441 obtained from CG-MD simulations.

1442 **Figure 4 – Figure supplement 1:** Analysis of the JAK2-FERM-SH2- PRLR-ICD<sub>LID1</sub> AA-MD simulation.

1443 **Figure 4 – Figure supplement 2:** Complementary analysis of Protein – lipid interactions of the JAK2-FERM-  
1444 SH2 PRLR-ICDLID1 complex obtained from CG-MD simulations

1445 **Figure 4 – Figure supplement 3:** Snapshots of the different binding states observed for the JAK2-FERM-  
1446 SH2 – PRLR-ICDLID1 complex with the complete structural model of JAK2

1447 **Figure 5 – Figure supplement 1:** Chemical shift perturbations of ICD<sub>K235-G313</sub> of A) WT B) K4E, C) GAG, D)  
1448 K4G and E)  $\phi$ 4G variants.


1449 **Figure 5 – Figure supplement 2:**  $^{15}\text{N}$   $R_2$  relaxation rates of ICD<sub>K235-G313</sub> of WT (grey bars), K4G (blue dots)  
 1450 and  $\phi$ 4G (red squares) variants.

1451

1452 **Supplementary files not directly related to any main figures:**

1453 **Movie 1:** Y State (STATE 2) from the JAK2-FERM-SH2 PRLR-ICD<sub>K235-E284</sub> complex simulated near a bilayer  
 1454 containing PI(4,5)P<sub>2</sub> : Representative trajectory showing State 2 (Y). Protein and lipids colored as in Fig. 4

1455 **Movie 2:** FLAT State (STATE 4) from the JAK2-FERM-SH2 PRLR-ICD<sub>K235-E284</sub> complex simulated near a  
 1456 bilayer containing PI(4,5)P<sub>2</sub> : Representative trajectory showing State 4 (Y). Protein and lipids colored as in  
 1457 Fig. 4




1458

1459 **Figure 2 – figure supplement 1.**  $^{15}\text{N}$ ,  $^1\text{H}$ -HSQC spectra of A) TMD<sub>F206-V240</sub> and TMD-ICD<sub>F206-S270</sub> in DHPC  
 1460 micelles, and (B) TMD-ICD<sub>F206-S270</sub> in POPC SUVs.


1461

1462



1463

1464 **Figure 2 – figure supplement 2.**  $C^\alpha$  secondary chemical shifts of ICD<sub>G236-Q396</sub>.



1465

1466

1467 **Figure 3 – figure supplement 1. Protein – lipid interactions of PRLR-ICD<sub>LID1</sub> obtained from CG-MD**

1468 **simulations using the martini 2.2 forcefield. (A-C) Protein – lipid-headgroups contact histograms from: (A)**


1469 **the PRLR-ICD<sub>LID1</sub> POPC:POPS (70:30) CGm2 simulation, (B) PRLR-ICD<sub>LID1</sub> POPC:POPS:PI(4,5)P<sub>2</sub> (90:5:5)**

1470 **CGm2 simulation and (C) PRLR-ICD<sub>LID1</sub> PRLR-ICD<sub>LID1</sub>POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) CGm2 simulation.**

1471

1472

1473




1473

1474 **Figure 3 – figure supplement 2: Complementary analysis of protein – lipid interactions of PRLR-**  
 1475 **ICD<sub>LID1</sub> obtained from CG-MD simulations using the martini 3.0b3.2 forcefield. (A-B) Protein – lipids**  
 1476 **contact histograms from the PRLR-ICD<sub>LID1</sub> POPC:POPS:PI(4,5)P<sub>2</sub> (90:5:5) CGm3<sub>pws10</sub> simulation. (A)**  
 1477 **Contacts between the protein and lipid headgroups. (B) Contacts between the protein and the acyl chains of the**  
 1478 **lipids. (C) RMSF of the BB beads obtained from the PRLR-ICD<sub>LID1</sub>POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10)**  
 1479 **CGm3<sub>pws10</sub> simulation (Magenta line) and the PRLR-ICD<sub>LID1</sub> POPC:POPS:PI(4,5)P<sub>2</sub> (90:5:5)**  
 1480 **CGm3<sub>pws10</sub> simulation (blue line). (D) Average PI(4,5)P<sub>2</sub> density map (xy-plane) taken from the PRLR-ICD<sub>LID1</sub> +**  
 1481 **POPC:POPS:PI(4,5)P<sub>2</sub>(90:5:5) CGm3<sub>pws10</sub> simulation. (E-F) Protein – lipids contact histograms from the**  
 1482 **PRLR-ICD<sub>LID1</sub> POPC:POPS (30:70) CGm3<sub>pws10</sub> simulation. (E) Contacts between the protein and lipid**  
 1483 **headgroups. (F) Contacts between the protein and the acyl chains of the lipids. In A-B and E-F protein – lipid**  
 1484 **contacts are defined as in Figure 3.**



1485



1486

1487

1488

1489

1490

1491


1492

1493

1494

**Figure 4 - Figure supplement 1: Analysis of the JAK2-FERM-SH2- PRLR-ICD<sub>K235-H300</sub> AA-MD simulation.** A) Average distance map between JAK2-FERM-SH2 and PRLR-ICD<sub>K235-H300</sub> obtained from the all-atom MD simulation. (B) Conservation of residues from PRLR in contact with JAK2-FERM-SH2 (see A). Residues with green label correspond to BOX1. (C-D) Conservation JAK2-FERM-SH2 oriented as state 2 (see Fig. 4E). Labeled residues correspond to residues that contact PRLR (see A) or that contact the lipids on states 2 and 4 (see Fig. 4E-H).

1495



1519

1520

1521

1522

1523

1524

1525

1526

1527

1528


1529

1530

1531

**Figure 4 - Figure Supplement 2. Complementary analysis of Protein – lipid interactions of the JAK2-FERM-SH2 PRLR-ICD<sub>K235-H300</sub> complex obtained from CG-MD simulations** (A) Number of simulations where protein is bound to the lower-leaf of the bilayer for the simulations containing: the JAK2-FERM-SH2 + PRLR-ICD<sub>K235-H300</sub> complex near a POPC:POPS(70:30) bilayer (blue line) and the JAK2-FERM-SH2 + PRLR-ICD<sub>K235-H300</sub> complex (red line) and the apo JAK2-FERM-SH2 (orange line) near a POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) bilayer. (B-C) Distribution of the orientations adopted by (B) the JAK2-FERM-SH2 + PRLR-ICD<sub>K235-H300</sub> complex when bound to lipids taken from the simulations with POPC:POPS(70:30) in the lower-leaflet and (C) the apo JAK2-FERM-SH2 when bound to lipids taken from the simulations with POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) in the lower-leaflet. (D-E) Representative protein-lipid contact histograms for State 1 observed for the JAK2-FERM-SH2 + PRLR-ICD<sub>K235-H300</sub> complex near a POPC:POPS(70:30) bilayer. (F-H) Representative protein-lipid contact histograms for States 1, 2 and 3 observed for the apo JAK2-FERM-SH2 near a POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) bilayer.

1532



1533

1534

1535

1536

1537

1538


1539

1540

1541

1542


**Figure 4 - Figure Supplement 3. Snapshots of the different binding states observed for the JAK2-FERM-SH2 – PRLR-ICD<sub>K235-H300</sub> complex with the complete structural model of JAK2 (obtained from AF2-EBI database). In each panel the CG JAK2-FERM-SH2 – PRLR-ICD<sub>K235-H300</sub> complex is depicted and colored as in Fig. 4. The full-length JAK2 model is shown in cartoon representation colored orange, near a POPC:POPS(70:30) bilayer. (F-H) Representative protein-lipid contact histograms for States 1, 2 and 3 observed for the apo JAK2-FERM-SH2 near a POPC:POPS:PI(4,5)P<sub>2</sub> (80:10:10) bilayer.**



1543

1544 **Figure 5 – Figure supplement 1:** Chemical shift perturbations of ICD<sub>K235-G313</sub> of A) WT B) K4E, C) GAG, D)

1545 K4G and E) ϕ4G variants.



1546

1547 **Figure 5 – Figure supplement 2:** <sup>15</sup>N R<sub>2</sub> relaxation rates of ICD<sub>K235-G313</sub> of WT (grey bars), K4G (blue dots)

1548 and ϕ4G (red squares) variants. Stars indicate signals excluded from the analysis either because it is a

1549 proline, signals are overlapping or a poor exponential fit.